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Abstract

The P2X7 receptor is an adenosine 5’-triphosphate (ATP)-gated ion channel
expressed

on

the

cell-surface

of many

cell

types,

including

cells of

haematopoietic origin and epithelial cells. Upon prolonged activation by
extracellular ATP, P2X7 has the ability to form pores permeable to large organic
cations such as ethidium+ and YO-PRO-12+. P2X7 activation leads to the
stimulation of the NALP3 inflammasome and the subsequent release of the proinflammatory cytokines interleukin (IL)-1β and IL-18.
The first aim of this study was to confirm the presence or absence of P2X7 and
NALP3-related components in Madin-Darby canine kidney (MDCK) epithelial
cells

and

lipopolysaccharide

(LPS)-primed

canine

monocytes.

Reverse

transcriptase (RT)-PCR detected the presence of P2X7, NALP3, caspase-1, IL-1β
and IL-18 mRNA in MDCK cells and monocytes. The identity of each transcript,
except IL-1β due to its small size, was confirmed by sequencing. This data
suggests that MDCK cells will provide a useful model cell line to study the role
of P2X7 and NALP3-related components in kidney epithelial cells and renal
disorders. Moreover, these results indirectly support our previous observations
that P2X7 activation induces IL-1β from LPS-primed canine monocytes.
The second aim of this study was to determine if ATP or the Toll-like receptor
(TLR) ligands, LPS or lipoteichoic acid (LTA), induce IL-1β release from MDCK
cells and in whole canine blood. ELISA measurements failed to detect IL-1β
release from MDCK cells despite examining various combinations of ATP, LPS
and/or nigericin (which induces IL-1β release independently of P2X7). Further
xiii

studies are required however to determine whether MDCK cells can release IL1β. In contrast to MDCK cells, LPS and ATP but not LTA induced IL-1β release
in whole blood. Moreover, ATP-induced IL-1β release in whole blood required
priming with LPS. A role for P2X7 in LPS- and ATP-induced IL-1β release in
blood however could not be established, as the P2X7 antagonist AZ10606120
failed to impair IL-1β release. Further studies are required to determine if
either or both of these processes require P2X7 activation.
The third aim of this study was to sequence and pharmacologically
characterise a recombinant canine P2X7 receptor cloned from an English
Springer Spaniel. Sequencing of the cloned receptor revealed two nonsynonymous (missense) single nucleotide polymorphisms (SNPs): Leu440Phe
and Pro452Ser. Immunoblotting confirmed the expression of P2X7 protein in
canine

P2X7-transfected

HEK

293

cells.

Moreover,

flow

cytometric

measurements demonstrated that ATP induced ethidium+ (314 Da) uptake into
P2X7-transfected but not mock-transfected HEK 293 cells in a time-dependent
manner. The P2X7 agonists ATP, 3’-O-(4-benzoyl)benzoyl ATP (BzATP) and
adenosine 5’-O-(3-thiotriphosphate) (ATPγS) induced ethidium+ uptake into
P2X7-transfected HEK 293 cells in a concentration-dependent manner with
EC50 values of 253 µM, 13 µM and 438 µM respectively. In contrast, adenosine
5’-diphosphate (ADP), uridine 5’-triphosphate (UTP) and α,β-methylene ATP
(α,β-meATP) failed to induce ethidium+ uptake into these cells. The P2X7
antagonists A438079, AZ10606120, AZ11645373, BBG and KN-62 completely
impaired ATP-induced ethidium+ uptake into P2X7-transfected HEK 293 cells
with IC50 values of 190 nM, 11 nM, 7 nM, 1110 nM and 19 nM respectively.
Finally, ATP induced YO-PRO-12+ (375 Da) and propidium2+ (415 Da) uptake
xiv

into P2X7-transfected cells. Collectively, the recombinant canine P2X7 receptor
demonstrated similar characteristics to that of native canine and recombinant
human P2X7. Thus, P2X7 drugs developed to block P2X7 in humans may also
be of therapeutic value in dogs.
The last aim of this thesis was to confirm if the relative monocyte P2X7
function varies between dogs and to determine if this variation is due to SNPs
in the P2RX7 gene. Flow cytometric measurements of ATP-induced YO-PRO-12+
uptake into peripheral blood canine monocytes confirmed that the relative
P2X7 function varied between dogs and within breeds. Flow cytometric
measurements also demonstrated that the relative P2X7 function of human
monocytes

varies

between

subjects

and

over

time.

Amplification

and

sequencing of the canine P2RX7 gene of 19 dogs and MDCK cells identified four
non-synonymous SNPs: Phe103Leu (exon 3), Arg270Cys (exon 8), Arg365Gln
(exon 11), and Pro452Ser (exon 13). The dogs for which we had both functional
data and genomic DNA (n = 62) were screened for the above SNPs and the
resulting genotypes were compared to relative P2X7 function. Three of the
SNPs (Phe103Leu, Arg365Gln and Pro452Ser) did not correspond with a
change in P2X7 function. In contrast, the Arg270Cys SNP was associated with
a loss-of-function in P2X7, however this finding was restricted to one dog, as
well as MDCK cells which have low P2X7 function. Future studies using
mutant P2X7 receptors, obtained by site-directed mutagenesis, are required to
explore if any of these SNPs alter P2X7 function.
This thesis forms a part of an ongoing study investigating the role of canine
P2X7 in inflammation and immunity. The confirmation of P2X7 in canine
xv

monocytes and MDCK cells, and the identification of SNPs in the canine P2RX7
gene will provide future opportunities to investigate the role of the P2X7
receptor and its gene in canine health and disease.

xvi

Chapter 1: Introduction

1.1 Purinergic signalling
Extracellular purines and pyrimidines such as adenosine,
triphosphate

(ATP),

triphosphate (UTP)

adenosine

5’-diphosphate

(ADP)

adenosine 5’-

and

uridine

5’-

act as signalling molecules through cell surface-bound

purinoreceptors. These receptors are widely distributed throughout the body
and mediate a wide range of biological responses upon activation (Ralevic and
Burnstock, 1998). In 1978, Burnstock distinguished between two major
subtypes of purinoreceptors; P1 and P2 receptors, which are selective for
adenosine, or ATP and ADP respectively (Table 1.1) (Burnstock, 1978). P2
receptors have been further divided into two families consisting of ligand-gated
ion channels (P2X) and G protein-coupled

receptors (P2Y) (Burnstock and

Kennedy, 1985).
Table 1.1: Purinoreceptor families

P1 receptors

P2X receptors

P2Y receptors

Natural ligands

Adenosine

ATP
ADP

Type

G protein-coupled

Ion channel
Cation-selective pore*

G protein-coupled

Subtypes

A1, A2A, A2B, A3

P2X1-7

P2Y1,2,4,6,11,12,13,14

ATP
ADP
UTP
Adenine dinucleotides

* P2X2,4,5 and 7 receptors. Adapted from Ralevic and Burnstock (1998).

1.1.1 The release of intracellular ATP
ATP is a purine nucleoside triphosphate, which is synthesized during oxidative
1

phosphorylation. It is utilized as a source of chemical energy available for all
living cells, as well as an extracellular signalling molecule acting on
purinoreceptors (Bodin and Burnstock, 2001). ATP can be released by cytolysis
from damaged and dying cells in response to mechanical distortion, osmotic
swelling, hypoxia, inflammatory conditions or to stimulation by some agents
(Burnstock, 2007). Alternatively, ATP can be released as a physiological
mechanism from healthy cells. The transport mechanism by which ATP is
released from these cells is still being debated (Burnstock, 2007, Abbracchio et
al., 2009). Exocytic vesicular release of ATP have been demonstrated in both
neuronal cells, where ATP functions as a classic neurotransmitter, and in nonneuronal cells such as osteoblasts, epithelial and endothelial cells (Bodin and
Burnstock, 2001). Other proposed mechanisms of ATP release include
facilitated

diffusion

by

nucleotide

ATP-binding

cassette

transporters,

electrodiffusional movement through ion channels such as connexin or
pannexin hemi-channels, plasmalemmal voltage-dependent anion channels
and P2X7 receptors (Burnstock and Verkhratsky, 2012). ATP can also be
released from microbial flora and pathogens (Koshlukova et al., 1999),
providing an alternative source of extracellular ATP other than that released
from the host.

1.1.2 Regulation of extracellular ATP
The concentrations of extracellular ATP are closely regulated by a number of
enzymes termed ectonucleotidases, which have their catalytic site on the
extracellular side of the cell membrane (Novak, 2003). After release, ATP is
2

rapidly degraded to ADP, adenosine 5’-monophosphate (AMP) or adenosine.
These nucleotides are ligands for a range of different purinoreceptors and thus
can mediate a variety of physiological responses. The enzymes responsible for
this degradation include ecto-nucleoside triphosphate diphosphohydrolases,
ecto-nucleotide

pyrophosphatase/phosphodiesterases,

ecto-5’-nucleotidases

and alkaline phosphatases (Yegutkin, 2008). Ecto-nucleoside triphosphate
diphosphohydrolases and ecto-nucleotidepyrophosphatase/phosphodiesterases
hydrolyse ATP and ADP to AMP (Fig. 1.1), and ecto-5’-nucleotidases further
hydrolyze AMP to adenosine (Fig. 1.1). Alkaline phosphatases equally hydrolyze
tri-, di- and monophosphates (Abbracchio et al., 2009). ATP can also be resynthesized from AMP via ADP via backward ecto-phosphotransfer reactions by
nucleotide diphosphate kinases and ecto-adenylate kinases (Fig. 1.1) (Yegutkin
et al., 2002).
NDP

AK

5’-NT

E-NTPDase

E-NTPDase

E-NPP
Figure 1.1 Mechanisms of ATP degradation and re-synthesis on the cell surface.
Extracellular adenosine 5’-triphosphate (ATP) can be degraded to adenosine 5’diphosphate (ADP), adenosine 5’-monophosphate (AMP) and adenosine by ectonucleoside

triphosphate

diphosphohydrolases

pyrophosphatase/phosphodiesterases

(E-NPP),

(E-NTPDase),

ecto-nucleotide

ecto-5’-nucleotidases

(5’-NT)

and

alkaline phosphatases (not shown). An opposite ATP-synthesising pathway is mediated
by nucleotide diphosphate kinases (NDPK) and ecto-adenylate kinases (AK).
3

1.2 The P1 receptor family

P1 receptors are G-protein coupled cell surface receptors that are sensitive to
adenosine (Ralevic and Burnstock, 1998). Four subtypes (A1, A2A, A2B and
A3) have been described on the basis of their molecular structures, tissue
distribution, biochemical and pharmacological properties. These receptors
range in size from 266 to 412 amino acids with a mass of 30 to 45 kDa after
glycosylation. P1 receptors, similar to other G-protein coupled receptors, have
seven transmembrane domains, with the N-terminus on the extracellular side
and the C-terminus on the cytosolic side (Ralevic and Burnstock, 1998). A1
and A3 subtypes primarily interact with Gi proteins to inhibit adenylyl cyclase
and modulate ion channels. In addition, A1 receptor activation has been linked
to various kinase pathways such as phosphoinositide 3 and mitogen-activated
protein kinases (Fredholm et al., 2000). A2A and A2B subtypes are
predominantly coupled with Gs proteins to cause an increase in intracellular
cAMP (Brown et al., 2008).
P1 receptors are widely expressed on cells throughout the body, including
neutrophils,

mast

cells,

monocytes,

macrophages,

dendritic

cells

and

lymphocytes (Brown et al., 2008). Their physiological role varies between
tissues and includes reduction of neuronal activity (A1) (Ralevic and
Burnstock, 1998), and downregulation of the production of pro-inflammatory
cytokines and free radicals (A2A) during ischaemia (Hasko et al., 2008). P1
receptors are also involved in activation of mast cells (A2B), release of allergic
mediaters (A3), vasoconstriction, inhibiton of renin secretion, inhibition of
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neurotransmitter release in the kidney (A1), and vasodilation in smooth muscle
and endothelial cells (A2B) (Ralevic and Burnstock, 1998).

1.3 The P2Y receptor family

P2Y receptors are G-protein coupled cell surface receptors that are sensitive to
ATP,

ADP,

UTP,

uridine

5’-diphosphate

(UDP)

and

nucleotide

sugars

(Boeynaems et al., 2012). These receptors range in size from 308 to 377 amino
acids with a mass of 41 to 53 kDa after glycosylation (Ralevic and Burnstock,
1998). All P2Y receptors have seven transmembrane domains with extracellular
N-terminus and intracellular C-terminus (Abbracchio et al., 2006). The P2Y
family consist of eight members (P2Y1,2,4,6,11,12,13 and 14) which are
further subdivided into two groups based on structural features (protein
sequence) and their binding to specific G-proteins. The P2Y1,2,4,6,11
subgroup is mainly coupled to Gq proteins to activate the phospholipase C
inositol triphosphate signalling pathway to cause the release of Ca2+, while the
P2Y12,13,14 subgroup predominantly couple to Gi proteins to inhibit adenylyl
cyclase and modulate ion channels (Abbracchio et al., 2009).
P2Y receptors are widely distributed throughout the body, with one or more
subtype found viritually on all cells. This includes nerve, glial, muscle cells and
immune cells such as eosinophils, mast cells, monocytes, macrophages,
dendritic cells and lymphocytes. P2Y receptors can also be detected in
endocrine, adipose, exocrine, gut, liver, kidney, bladder, lung, bone, epithelial
and endothelial cells and platelets (Abbracchio et al., 2006). Known functions
of P2Y receptors include various inflammatory responses such as chemotaxis
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(P2Y2 and 12), phagocytosis (P2Y6), platelet aggregation (P2Y1 and 12),
epithelial hydration (P2Y2 and 4) and bone formation and resorption (P2Y2,6
and 13) (Boeynaems et al., 2012).

1.4 The P2X receptor family

P2X receptors are ATP-gated cation cannels permeable to Na+, Ca2+ and K+
upon activation. Seven genes encoding for P2X subunits (P2X1-7) have been
identified, with subunit proteins varying in size from 379 (P2X6) to 595 (P2X7)
amino acids (Khakh et al., 2001). Functional receptors are formed as either
homomeric (P2X1-5 and P2X7) or heteromeric (P2X1/2, P2X1/5, P2X2/3,
P2X2/6 and P2X4/6) trimers (Abbracchio et al., 2009). All P2X receptor
subunits have consensus sequences for N-linked glycosylation, some of which
are required for trafficking to the cell surface (North, 2002).
The P2X receptors are widely but specifically distributed throughout the body.
P2X receptors can be found on neurons, microglia, endothelial cells, colon,
heart, liver, lung, kidney, endocrine glands, osteoblasts, skeletal muscle,
fibroblasts and blood cells, including erythrocytes, platelets, and leukocytes
(Burnstock et al., 2010). The physiological functions of P2X receptors include
fast and slow neurotransmission at central synapses (P2X2,4 and 6), initiation
of sensory signalling pathways, such as taste, chemoreception and neuropathic
pain (P2X2,3,4 and 7), control of blood flow by contraction or relaxation of
smooth muscle cells (P2X1,4 and 7), regulation and secretion of exocrine
hormones (P2X4 and 7), intestinal motility (P2X2 and 3), regulation of
proinflammatory

mediators,

cell

proliferation

and

cell

death

(P2X7)
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(Surprenant and North, 2009, Burnstock et al., 2010, Kaczmarek-Hájek et al.,
2012).

1.4.1 General structure of P2X receptors
Non-denaturing protein electrophoresis first showed that P2X receptors form
stable oligomers of three subunits (Nicke et al., 1998). This trimeric structure
was confirmed by crystallography of the P2X4 receptor in the zebrafish (Fig 1.2)
(Kawate et al., 2009). Each P2X receptor subunit is comprised of two
hydrophobic transmembrane domains, leaving most of the protein outside of
the cell as a ~280 amino acid hydrophilic loop, and the N- and C-terminus on
the cytoplasmic side (North, 2002, Ralevic and Burnstock, 1998). The ATPbinding site and sites for antagonists and modulators are found in the
ectodomain (Khakh et al., 2001). Eight highly conserved residues (Lys69,
Lys71, Phe183 and Thr184 from one subunit, and Asn288, Phe289, Arg290
and Lys308 from another subunit; numbering taken from rat P2X2) that are
critical for ATP sensitivity have been identified by mutagenesis studies. These
contribute to a positively charged pocket large enough to accomodate ATP
(Browne, 2012). Recently, a crystal structure of the zebrafish P2X4 receptor in
complex with ATP confirmed that ATP-binding sites are found at each of the
three subunit interfaces (Hattori and Gouaux, 2012). The binding site for P2X
antagonists appears to be antagonist- and receptor-specific. For example, in
the case of P2X1 receptor sensitivity to suramin, the Lys138 residue is critical
(Sim et al., 2008). Conversely, for the human P2X7 receptor, antagonism by
GW791343, KN-62 and AZ11645373 is dependent on the Phe95 residue
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(Michel et al., 2009). Thus, the identification of residues involved in antagonistbinding is crucial for the development for potent and selective P2X receptor
antagonists.

Figure 1.2: The structure of P2X receptors. (A,B) The crystal structure of the P2X4
receptor in zebrafish demonstrate that one P2X receptor consists of three subunits.
The different subunits are shown in different colour, (A) viewed parallel to the
membrane plane and (B) from the extracellular side. Adapted from Kawate et al.
(2009).

1.5 The P2X7 receptor

Similarly to other P2X receptors, P2X7 exhibits ion channel activity upon
activation by extracellular ATP, which allows the rapid flux of Na+, Ca2+ and K+
across the cell membrane. However, after sustained stimulation by ATP, P2X7
has the ability to form pores permeable to organic cations. This leads to a
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range of inflammatory and other responses. P2X7 have been linked to a
number of disorders, and thus is attracting attention as a therapeutic target.

1.5.1 Cloning of the P2X7 receptor
P2X7 was first named P2Z but was identified as a P2X receptor when cloned
from rat brain macrophages by Surprenant et al. (1996). Subsequently, the
P2X7 receptor was cloned from different tissues of various species including
human monocytes (Rassendren et al., 1997), mouse microglia (Chessell et al.,
1998), Xenopus Laevis stomach (Paukert et al., 2002), guinea pig brain (Fonfria
et al., 2008) and finally from dog heart (Roman et al., 2009). The sequence
similarities between the P2X7 receptors varies from 43-86%, with the canine
P2X7 receptor having the highest sequence identity compared to the human
P2X7 receptor (86%) (Fig. 1.3; Table 1.2). Similar to human, rat and mouse
orthologues, the canine receptor contains 595 amino acids. Of note however,
compared to human and rodent P2X7, canine P2X7 contains an additional
residue in the extracellular loop (Thr284) and has a deletion of Val538 in the
C-terminus (Roman et al., 2009). Compared to the reference sequence from
National

Center

for

Biotechnology

Information

(NCBI;

accession

no:

NM_001113456.1) deduced from a Boxer (Lindblad-Toh et al., 2005), the
canine P2X7 receptor cloned from a Beagle contained one non-synonymous
single nucleotide polymorphism (SNP) in position 103 (Phe103Leu) (Roman et
al., 2009) (Fig. 1.3).
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Figure 1.3: ClustalW alignment of the amino acid sequence from the NCBI
human P2X7 reference sequence (accession no: Q99572), canine P2X7 reference
sequence (accession no: NM_001113456.1) and canine P2X7 cDNA cloned by
Roman et al. (2009).

10

Table 1.2: Percent sequence identity between human, rat, mouse, guinea pig, dog
and X. Laevis P2X7 receptors.

Human
Rat
Mouse

Human

Rat

Mouse

Guinea pig

Dog

X. Laevis

100

80

81

77

86

45

100

85

74

76

45

100

75

76

45

100

73

43

100

44

Guinea pig
Dog
X. Laevis

100

1.5.2 The structure of P2X7 receptors
Crystallography studies have not been performed for P2X7, although the P2X4
structure together with alternative structure prediction indicate that the P2X7
subunit is structurally similar to other P2X receptors (section 1.4.1). P2X7
contains two transmembrane domains, and the N- and C-terminal domains on
the intracellular side (Fig. 1.4) (Mager et al., 2006). The extracellular loop
separating the two transmembrane domains contains 10 cysteine residues that
form disulfide bonds and six-stranded β–pleated sheets (Freist et al., 1998).
The main distinctive feature of P2X7 compared to other P2X receptors is the
long intracellular C-terminal domain (244 amino acids), of which at least 177
amino acids are essential for the pore-formation (Surprenant et al., 1996b).
Functional heterotrimeric P2X4/7 receptors have been observed (Guo et al.,
2007), however homotrimeric P2X7 receptors appears to be the dominant
assembly state of native P2X7 subunits (Nicke, 2008).

11

Figure 1.4: The schematic structure of a single P2X7 subunit. The P2X7 receptor
subunit contains two transmembrane domains separated by an extracellular loop. The
N-terminal and the long C-terminal domain are found intracellularly. Adapted from
Wiley et al. (2011).

1.5.3 The distribution of P2X7 receptors
P2X7 is expressed in various cell types throughout the body. The highest levels
of expression are found predominantly on cells of hematopoietic origin such as
macrophages, dendritic cells, monocytes, natural killer cells, lymphocytes and
erythrocytes. P2X7 is also present on mast cells, eosinophils, various epithelial
and endothelial cells, fibroblasts and exocrine glands. In the nervous system,
P2X7 is expressed on microglia, astrocytes, oligodendrocytes, ependymal cells,
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Schwann cells, satellite cells and some neurons (Kaczmarek-Hájek et al., 2012,
Wiley et al., 2011, Burnstock and Knight, 2004).

1.5.4 Activation of P2X7
Activation of P2X7 by extracellular ATP causes the opening of a non-selective
cation channel within milliseconds, which allows the influx of Na+ and Ca2+,
and the efflux of cellular K+ (Fig. 1.4) (Wiley et al., 2011). Compared to other
P2X

receptors,

extracellular

P2X7

ATP

for

require

10-100

activation

(Jarvis

times
and

higher

concentrations

Khakh,

2009).

of

Prolonged

stimulation with ATP results in the slow development over tens of seconds of a
reversible secondary non-selective pore permeable to large organic molecules
with molecular weight up to 900 Da, including choline+ (104 Da), N-methyl-Dglutamine (NMDG; 195 Da) and fluorescent dyes such as ethidium+ (314 Da),
YO-PRO2+ (375 Da), propidium2+ (415 Da) and lucifer yellow2- (443 Da). This
property has also been observed for P2X2, P2X4 and P2X5 receptors (Virginio
et al., 1999b, Khakh et al., 1999, Bo et al., 2003), thus the ability to form pores
is not unique to P2X7. Nevertheless the P2X7-induced uptake of dyes allows
for the quantitative measurement of receptor function by fluorescent detection
techniques such as flow cytometry (Jursik et al., 2007).
There has been much controversy regarding the mechanism of the P2X7 poreformation (for review see Pelegrin, 2011). It has been suggested that the pore is
a result of dilation of the intrinsic P2X7 channel itself (Jiang et al., 2005, Yan
et al., 2010, Virginio et al., 1999a), however growing evidence suggest that
P2X7-activation induces the activation of a second pore protein (directly or
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indirectly via second messengers), such as the hemichannel pannexin-1 (Fig.
1.5) (Pelegrin and Surprenant, 2006, Iglesias et al., 2008, Locovei et al., 2007).
Recently, however, a pannexin-1 knockout mice study demonstrated that
pannexin-1 is not required for P2X7-mediated pore-formation (Qu et al., 2011).
Although other evidence suggests that P2X7-activated pannexin-1 mediates
YO-PRO2+ uptake into cells by releasing cellular ATP which then stimulates
P2X7 thus providing a positive feedback loop (Qu et al., 2011, Dahl and Keane,
2012). Moreover, P2X7-activation has recently been shown to induce at least
two selective permeation pathways that may involve an exchanger or
transporter which mediates dye uptake instead of or in addition to a pore
protein (Fig. 1.5) (Cankurtaran-Sayar et al., 2009, Marques-da-Silva et al.,
2011, Schachter et al., 2008). In macrophages, but not in human embryonic
kidney

cells,

separate

pathways

for

cation

and

anion

uptake

were

demonstrated (Cankurtaran-Sayar et al., 2009, Schachter et al., 2008).
However, the true mechanism of the P2X7 pore formation remains unidentified.
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Figure 1.5: Schematic representation of ATP-induced activation of P2X7.
Activation of P2X7 by extracellular ATP causes the opening of a non-selective cation
channel within milliseconds. Prolonged exposure to ATP results in the opening of a
pore, by which the mechanism is controversial. The current model involves a dilation
of the P2X7 channel itself, leaving it permeable to some larger molecules, such as Nmethyl-D-glutamine (NMDG). In addition, at least one secondary pore protein is
thought to be involved. Adapted from Pelegrin (2011).

1.5.5 Signalling events downstream of P2X7 activation
Activation of P2X7 mediates a range of downstream signalling pathways. A
central role for the receptor in inflammatory responses has been established.
P2X7-activation, together with a co-stimulus such as activation of Toll-like
receptors (TLRs) by the bacterial products lipopolysaccharide (LPS) or
lipoteichoic acid (LTA), leads to the upregulation and activation of the NALP3
inflammasome and the subsequent release the pro-inflammatory cytokines
interleukin (IL)-1β and IL-18 (discussed further in section 1.7.3) (Piccini et al.,
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2008). The cellular efflux of K+ and influx of Ca2+ following P2X7-activation
causes the activation of phospholipase A2 and phospholipase C, which is
involved in processing and release of IL-1β (Andrei et al., 2004, Alzola et al.,
1998). P2X7-activation also causes activation of phospholipase D which is
required for killing of intracellular Mycobacterium tuberculosis (Kusner and
Adams, 2000), the formation of reactive oxygen species (Sperlágh et al., 1998),
activation of the transcription factor nuclear factor-κB via mitogen-activated
protein kinase (Ferrari et al., 1997), and the activation of metalloproteases and
subsequent shedding of cell surface molecules such as CD23, CD27 and
CD62L (Gu et al., 1998, Moon et al., 2006). Membrane blebbing and
subsequent apoptosis are also well established downstream effects following
prolonged activation of P2X7 (Franceschi et al., 1996, Wilson et al., 2002).

1.6 The pharmacology of P2X7 receptors

The agonist and antagonist profile of each P2X receptor is unique. The
pharmacology specific of P2X7 is discussed below.

1.6.1 P2X7 receptor agonists
P2X7 is activated by a variety of agonists, although their potency and
specificity varies. The most potent agonist of P2X7 is 2,3-O-(4-benzoylbenzoyl)ATP (BzATP) which was previously considered selective for P2X7, however
BzATP can also activate most other P2X receptors (Bianchi et al., 1999). ATP
activates P2X7 at relatively high concentrations compared to other P2X
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receptors, and the nucleotide is 10-fold less potent than BzATP at human P2X7
receptors (Donnelly-Roberts et al., 2009). Other nucleotides are weakly potent
P2X7-agonists, including 2-methylthio-ATP (2-meSATP) and adenosine 5’-O-(3thiotriphosphate) (ATPγS). Agonists for other P2X and P2Y receptors, including
ADP, AMP, α,β-methylene-ATP (α,β-meATP), UTP and UDP are ineffective as
P2X7 agonists (Donnelly-Roberts et al., 2009).
The agonist profile of P2X7 varies in a species-dependent manner. For
instance, ATPγS and 2-meSATP are weak agonists at the human P2X7
receptor, but show no significant activity at rat or mouse P2X7 (DonnellyRoberts et al., 2009). BzATP has similar potency at the human, rat and canine
P2X7 receptor, however, this nucleotide is 100-fold less potent at the mouse
P2X7 receptor (Donnelly-Roberts et al., 2009, Stevenson et al., 2009, Roman et
al., 2009). This increased sensitivity to BzATP in rat P2X7 compared to mouse
P2X7 has been attributed to the Lys127 and Asn284 residues found in the rat
P2X7 receptor (Young et al., 2007). In the human and canine P2X7 receptors
polar or positively charged residues are also found in these positions; in
contrast the mouse P2X7 receptor contains nonpolar (Ala127) and negatively
charged (Asp284) residues at these sites. BzATP is considered a complete
agonist of human, rat, mouse and canine P2X7 (Donnelly-Roberts et al., 2009,
Stevenson et al., 2009), however the study by Roman et al. (2009) suggests that
BzATP is only a partial agonist of canine P2X7. The reason for this difference
with BzATP for the canine P2X7 receptor remains unknown, but may be due to
differences in assays or dog breed. Or note however, BzATP is also considered a
partial agonist of guinea pig P2X7 (Fonfria et al., 2008).
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Human and rat P2X7 are 10-fold more sensitive to ATP compared to mouse
P2X7 (Young et al., 2007, Donnelly-Roberts et al., 2009). The differences
between rat and mouse receptor sensitivity have also been attributed to the
Asn284 residue in rat P2X7 (Young et al., 2007). The study by Roman et al.
(2009) reported that ATP showed similar agonist potency between human and
canine P2X7, which contradicts the study by Stevenson et al. (2009), where
human P2X7 was four-fold more sensitive to ATP compared to canine P2X7.
Again, it should be noted, however, that the study by Roman et al. (2009) used
recombinant P2X7 cloned from a Beagle, whereas the study by Stevenson et al.
(2009) used native P2X7 from English Springer Spaniel erythrocytes. Thus this
may account for the differences in ATP sensitivity between these two studies.

1.6.2 P2X7 receptor antagonists
P2X7 receptor function can be impaired by a range of antagonists of varying
specificity. Pyridoxal phosphate-6-azophenyl-2-4-disulphonic acid (PPADS) can
impair human, canine and rodent P2X7 receptors, as well as other homomeric
and heteromeric P2X receptors. Of the non-specific P2X7 antagonists, KN-62
and calmidazolium, which also inhibit calmodulin-dependent kinases, are
potent inhibitors of human, canine and mouse receptors, or human and rat
receptors, respectively. (Gever et al., 2006, Donnelly-Roberts et al., 2009,
Roman et al., 2009). Brilliant Blue G (BBG) impairs P2X7 at nonomolar
concentrations for human, canine and rodent receptors (Roman et al., 2009,
Donnelly-Roberts et al., 2009). Of note, BBG also impairs P2X4 and some P2Y
receptors at low micromolar concentrations, and is a charged protein dye and
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thus is likely to bind to other molecules to alter their function (Syed and
Kennedy, 2012).
Recently, a number of potent and specific P2X7 antagonists have been made
commercially available, including A438079 (Nelson et al., 2006), A740003
(Honore et al., 2006), AZ10606120 (Michel et al., 2008) and AZ11645373
(Stokes et al., 2006) (Table 1.3). Among these antagonists, A438079 and
A740003 are the least species-selective P2X7 inhibitors with similar efficacy at
the human, rat and mouse receptor (Donnelly-Roberts et al., 2009).
AZ10606120 is a potent non-competitive inhibitor of human, rat and canine
receptors (Michel et al., 2008, Roman et al., 2009). AZ11645373 is active at low
to mid nanomolar concentrations against human and canine P2X7 receptors,
whereas higher concentrations are needed to impair mouse and guinea pig
receptors. Rat P2X7 receptors are essentially insensitive to this compound
(Michel et al., 2009, Stokes et al., 2006). Lastly, GW791343 impairs human
and canine P2X7 receptors with similar potencies, although it has no effect at
mouse receptors and potentiates rat P2X7 receptors (Michel et al., 2008). A
number of other P2X7-specific antagonists have also been developed, but these
are patented and not readily available (Syed and Kennedy, 2012). In addition,
anti-P2X7 monoclonal antibodies (clones L4 and 1F11) can also block human
P2X7 receptor (Buell et al., 1998a) and mouse P2X7 receptor (Kurashima et al.,
2012), respectively. Thus, this opens up the possibility of developing blocking
anti-P2X7 antibodies with therapeutic potential.
P2X7 receptors are also sensitive to their extracellular milieu. The study by
Virginio, et al. (1997) showed that divalent cations, such as Ca2+, Mg2+, Zn2+
19

and Cu2+, impair rat P2X7-evoked currents with half-maximal inhibitory
concentrations (IC50) of 2.9 mM, 0.5 mM, 11 µM and 0,5 µM respectively. The
relative potencies for blocking BzATP-induced YO-PRO2+ uptake were as
follows: Cu2+ > Cd2+ = Zn2+ > Ni2+ >> Mg2+ = CO2+ > Mn2+ > Ca2+ = Ba2+ >> Sr2+
(Virginio et al., 1997). Thus, the relative amount of cations in media can affect
P2X7 including signalling events downstream of P2X7 activation.
Table 1.3: Antagonist potencies against recombinant P2X7 from various species.

IC50 (nM)
Antagonist

Human

Rat

Mouse

Dog

PPADSa

1200

1200

4900

ND

210

> 100 000

190

10

1900

580

190

49

930

100

650

ND

KN-62
BBG

a,b

a,b

A438079

a

A740003

a

93

100

720

ND

AZ10606120

b

2.6

28

ND

54

AZ11645373

c

35

3300

1500

40

b

GW791343
93
Potentiate
ND
200
Data obtained from a Donnelly-Roberts et al. (2009); b Roman et al. (2009);

c

Michel et

al. (2009). ND; Not Determined.

1.7 The physiological and pathophysiological role of P2X7 receptors

Studies of P2X7-deficient mice (Chessell et al., 2005, Solle et al., 2001b)
together with the known signalling events downstream of P2X7-activation
(section 1.5.5) have contributed to establishing a physiological role for the
receptor in inflammation and pain. P2X7 receptors have shown to be involved
in immune and inflammatory responses, including the processing and release
of pro-inflammatory cytokines such as IL-1β and IL-18, and the killing of
intracellular pathogens such as M. tuberculosis (tuberculosis) and Toxoplasma
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gondii (toxoplasmosis) (Wiley et al., 2011). A role for P2X7 receptors has also
been established in bone formation (Ke et al., 2003). P2X7 has been linked to a
range of inflammatory disorders such as rheumatoid arthritis, gout and
chronic inflammatory and neuropathic pain (Skaper et al., 2010). In addition,
P2X7 is known to modulate synaptic activity and neuron-glia signalling in the
brain, and have been linked to neurodegenerative disorders such as multiple
sclerosis (Narcisse et al., 2005), Alzheimer’s disease (Parvathenani et al., 2003)
and Parkinson’s disease (Baranyi et al., 2011). High levels of P2X7 have been
found in diverse tumors, and it has been suggested that the receptor has a role
in tumor metastasis and invasiveness of cancer cells (Jelassi et al., 2011). The
P2X7 receptor has also been linked to renal disorders, such as unilateral
ureteral obstruction (Goncalves et al., 2006), glomerulonephritis (Turner et al.,
2007, Taylor et al., 2009) and polycystic kidney disease (Xu et al., 2009).
Lastly, P2X7 has been associated with neuropsychiatric illnesses, such as
bipolar disease and major depression (Barden et al., 2006, Hejjas et al., 2009).

1.7.1 IL-1β
IL-1β is a member of the IL-1 cytokine family and is a key mediator of host
response to infection and inflammatory processes. IL-1β is produced from a
variety of cells, including activated monocytes, macrophages, dendritic cells, B
lymphocytes, natural killer cells and microglia (Ferrari et al., 2006, Dinarello,
2009). IL-1β is synthesized as a precursor molecule (pro-IL-1β; 31 kDa) in
response to bacterial products such as LPS, and host-derived inflammatory
factors (Dinarello, 2009). These molecules mediate signalling pathways via
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pattern recognition receptors (PRRs), including TLRs. However, a second
stimulus such as ATP is required to activate the cysteine protease caspase-1 to
mediate the proteolytic conversion of pro-IL-1β to mature, biologically active IL1β (17 kDa) (Dinarello, 2009). Although processing of pro-IL-1β into active IL1β is predominantly mediated by caspase-1, there are some caspase-1
independent pathways that process the precursor molecule extracellularly
such as cleavage by elastase, the neutrophil protease proteinase-3, matrix
metalloprotease 9, mast cell chymase and granzyme A (Coeshott et al., 1999,
Taylor et al., 2009, Xu et al., 2009, Wilson et al., 2002).
IL-1β exerts a wide range of pro-inflammatory biological activities, including
the induction of acute-phase protein synthesis and subsequent activation of
the complement system, phagocytosis, fever induction, vasodilation, local
tissue destruction and activation of lymphocytes (Gosslau et al., 2011). The
cytokine also plays a role in angiogenesis and tumor metastasis (Dinarello,
2009). Autoinflammatory diseases were originally characterised by recurrent
episodes of fever with inflammatory responses in multiple organs. These
diseases are now a part of a broader group that show elevated levels of IL-1β
and

include

familial

Mediterranean

fever,

arthiritis,

systemic

lupus

erythematosus, pericarditis, urate crystal arthiritis (gout) and type 2 diabetes
(Dinarello, 2009, Ferrari et al., 2006). This demonstrates the importance of IL1β as a therapeutic target.

1.7.2 IL-18
IL-18 was originally identified as an interferon (IFN)-γ-inducing factor, and is
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an important regulator of both innate and acquired immune responses
(Okamura et al., 1995). Similar to IL-1β, IL-18 is produced as a precursor
molecule (pro-IL-18; 23 kDa), which is cleaved by caspase-1 to the biologically
active cytokine (18 kDa) (Ferrari et al., 2006). In contrast to pro-IL-1β, pro-IL18 is synthesized and stored in the cytosol independent of an external signal
such as LPS (Puren et al., 1999).
IL-18 is secreted from a variety of cells, including monocytes, macrophages,
dendritic cells, fibroblasts and osteoblasts (McInnes et al., 2000). Secreted IL18 subsequently induces the synthesis of other cytokines, including IL-6, IL-8,
tumor necrosis factor (TNF)-α, IFN-γ and IL-1β. Moreover, the production of
several chemokines and adhesion molecules is induced by IL-18. Other
functions of IL-18 include the direct modulation of the activity of B- and Tlymphocytes, natural killer cells, dendritic cells and macrophages (McInnes et
al., 2000). Furthermore, similar to IL-1β, overproduction of IL-18 have been
shown to play a role in autoinflammatory and autoimmune diseases such as
rheumatoid arthritis, Crohn’s disease, macrophage activation syndrome, type 1
diabetes, psoriasis and graft-versus-host disease (Dinarello, 2009).

1.7.3 NALP3 inflammasome activation
Inflammasomes are large macromolecular complexes containing NOD-like
receptors (NLRs) such as NACHT-LRR-PYD-containing protein (NALPs) (Fig.
1.6) or ICE-protease activating factors (IPAFs), which act as intracellular
sensors for danger signals, including microbes and cell disruption. The NALP3
inflammasome is particularly well studied due to its prominent function in
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sterile inflammatory responses, antimicrobial responses, adjuvanticity and
hereditary autoinflammatory syndromes (Bauernfeind et al., 2011).

PYD

NALP3 inflammasome

Domains:

NALP3
LRR

CARD

NACHT

Caspase

ASC
PYD
Caspase-1

Figure 1.6: Schematic structure of the NALP3 inflammasome. NALP3 (NACHTLRR-PYD-containing protein) consist a leucine-rich repeat (LRR) domain, a nucleotide
binding domain (NACHT) and a pyrin domain (PYD). Upon activation, NALP3 recruits
apoptosis-associated speck-like protein containing a C-terminal CARD (ASC) via PYDPYD interactions and caspase-1 via caspase recruitment domain (CARD)-CARD
interactions to form a macromolecular complex – the NALP3 inflammasome. Adapted
from Bauernfeind et al. (2011).

Upon activation, the NALP3 inflammasome is formed by assembly of NALP3,
the adaptor protein apoptosis-associated speck-like protein containing a Cterminal CARD (ASC) via pyrin domain (PYD)-PYD interactions. The leucinerich repeats (LRR) are thought to sense the signals that lead to oligomerization
of the NACHT domain. Pro-caspase-1 is then recruited to the inflammasome by
via homotypic caspase recruitment domain (CARD)-CARD interactions and
subsequently activated. Activation of the NALP3 inflammasome and caspase-1
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results in the processing and release of the pro-inflammatory cytokines IL-1β
and IL-18 (Bauernfeind et al., 2011, Martinon et al., 2009).
NALP3 inflammasome activation can be triggered by a wide range of stimuli.
Microbes that can activate the inflammasome include influenza A virus,
adenovirus, Staphylococcus aureus, Escherichia coli and Neisseria gonorrhoe
(Bauernfeind et al., 2011). Although it is not completely understood how
microbes activate the NALP3 inflammasome, influenza A virus encodes an ion
channel protein (M2), which is thought to be involved in NALP3 inflammasomeactivation (Ichinohe et al., 2010). Moreover, activation by bacteria has been
attributed to specific bacterial pore-forming toxins, which allows the efflux of
cellular K+ (Fig. 1.7). These include Listerolysin O, nigericin (Mariathasan et al.,
2006), streptolysin (Harder et al., 2009) and maitotoxin (Gurcel et al., 2006).
Phagosomal materials such as crystals, particles and endogenous protein
aggregates can also activate NALP3. Gout-associated uric acid crystals,
including monosodium urate and calcium pyrophosphate dehydrate crystals,
have been shown to cause the activation of the NALP3 inflammasome and the
release of IL-1β (Martinon et al., 2006). Furthermore, it has been shown that
environmental pollutants consisting of inorganic crystalline material such as
crystalline silica and asbestos, which cause the pulmonary fibrotic disorders
silicosis and asbestosis respectively, work in a NALP3-dependent manner
(Hornung et al., 2008, Dostert et al., 2008). In addition, aluminium salts, which
are commonly used as adjuvants in vaccines, and endogenous protein
aggregates such as amyloid-β linked to Alzheimer’s disease induce the
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production of pro-inflammatory cytokines via the NALP3 inflammasome
(Hornung et al., 2008, Halle et al., 2008).

Figure 1.7: Molecular mechanisms involved in the activation of the NALP3
inflammasome. An initial priming step, such as the activation of pattern recognition
receptors, leads to the enhanced transcription of NALP3 (NLRP3) and pro-interleukin1β (pro-IL-1β). A second stimulus, such as ATP-induced P2X7-activation or pathogenderived pore-forming toxins, leads to the efflux of K+ and subsequent assembly and
activation of the NALP3 inflammasome comprising of NALP3, the protein apoptosisassociated speck-like protein containing a C-terminal CARD (ASC) and pro-caspase-1.
Caspase-1 is then activated and subsequently cleaves pro-IL-1β into mature IL-1β.
Lysosomal damage and reactive oxygen species (ROS) can also activate the NALP3
inflammasome (Bauernfeind et al., 2011).
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Lastly, the inflammasome can be activated by endogenous signals, such as
extracellular ATP via the activation of P2X7 (Fig. 1.7). The resulting drop in
cytosolic K+ concentrations stimulates the NALP3 inflammasome by a poorly
understood mechanism. However evidence indicates that the process may
involve the production of reactive oxygen species (ROS) and lysosomal
disintegration (Bauernfeind et al., 2011).
The level of NALP3 expression is also important for activation of the
inflammasome. Monocytes and macrophages require an initial priming step to
cause

the

enhanced

transcription

of

NALP3.

For

example,

microbial

components such as LPS, single-stranded RNA, peptidoglycans and CpG DNA
stimulate cell signalling through various PRRs including TLRs (Fig. 1.7). This
leads to the synthesis of NALP3 via the transcription factor NF-κB (Bauernfeind
et al., 2011, Martinon et al., 2009).
Following activation of the NALP3 inflammasome and the subsequent
generation of mature IL-1β in the cytosol (Fig. 1.7), the biologically active
cytokine is released from the cell via various mechanisms. These include the:
exocytosis of secretory lysosomes (Andrei et al., 2004) or endosome-derived
recycling multivesicular bodies (Qu et al., 2007); shedding of plasma
membrane microvesicles (Milius et al., 2007); or direct efflux via membrane
transporters (Panupinthu et al., 2008).

1.8 P2X7 receptor splice variants
The gene encoding the P2X7 receptor (P2RX7) consists of 13 exons and is
located on the human chromosome 12 (12q24.31) (Buell et al., 1998b). The
27

full-length protein defined as P2X7A is well characterised. In addition, nine
different naturally occurring splice variants have been identified in humans
(P2X7B-J) (Cheewatrakoolpong et al., 2005, Adinolfi et al., 2010, Feng et al.,
2006). Four of these, namely P2X7B, P2X7C, P2X7E and P2X7G, contain a
premature stop-codon in exon 10 resulting in a truncated C-terminal domain
(Cheewatrakoolpong et al., 2005). P2X7G and P2X7H contain an alternative
start codon and additional exon (N3) in the intron between exon 2 and 3, which
results in a non-functional protein lacking the first transmembrane domain.
P2X7B is of particular interest due to its wide tissue expression and
involvement in cell-growth and cancer. Recently, P2X7B was found to be coexpressed with P2X7A, forming modulated receptors that lose its proapoptotic
activity typical of P2X7 (Adinolfi et al., 2010). P2X7J lacks exon 8 resulting in a
truncated protein with 10 alternate amino acids at the C-terminus. This
variant has also been identified in cancer cells, and has been shown to inhibit
P2X7A-mediated apoptosis (Feng et al., 2006). The P2X7I variant results from a
rare point mutation between exon 1 and 2, causing a null allele (Skarratt et al.,
2005), and has been linked to increased susceptibility to tuberculosis
(Fernando et al., 2005). Other splice variants lack one or more of the 13 exons
of

P2X7A

(Cheewatrakoolpong

et

al.,

2005),

but

their

role

remains

undetermined.
Three P2X7 splice variants have been identified in mice (Nicke et al., 2009,
Masin et al., 2012). A fully functional variant, P2X7K, express an alternative
exon 1, and subsequently a different N-terminus and first transmembrane
domain. This isoform is more sensitive to agonists and has increased poreforming activity. Interestingly, P2X7K escapes silencing in a commonly used
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P2X7 knockout mouse strain (Glaxo) (Nicke et al., 2009). More recently, two
novel splice variants with alternative exon 13 (P2X713b and P2X713c) were
identified (Masin et al., 2012). These truncated C-terminal variants were
expressed in a different P2X7 knockout mouse strain (Pfizer) and showed
decreased receptor function compared to the full-length protein. When coexpressed with P2X7A, P2X713b exhibited a dominant negative effect on
surface expression, indicating that it may play a role in suppressing normal
P2X7 function (Masin et al., 2012).
Several splice variants have also been found in cloned canine P2X7 receptors
(Roman et al., 2009). One isoform contains an alternative splice site within
exon 13, resulting in a truncated C-terminal domain lacking amino acid
residues 432-522. Another isoform lacks exon 7, causing a frame-shift and the
introduction of a premature stop-codon. If translated, this causes a truncated
P2X7 receptor consisting of residues 1-205 and an additional 13 unique
residues at the C-terminus (Roman et al., 2009).

1.9

P2X7 single nucleotide polymorphisms

The human P2RX7 gene is highly polymorphic, containing over 1500 single
nucleotide polymorphisms (SNPs) (http://www.ncbi.nlm.nih.gov/snp). The
majority of these SNPs are intronic or synonymous, however over 100 nonsynonymous amino-acid altering SNPs have been identified, of which 17 have
been characterised for phenotype (Fig. 1.8; Table 1.4) (Sluyter and Stokes,
2011). The most extensively studied variant is the Glu496Ala (rs3751143) lossof-function SNP, which has shown to impair P2X7 pore formation (Gu et al.,
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2001) without affecting channel activity (Boldt et al., 2003). A variety of
functional defects have been observed in the presence of this mutation
including impaired P2X7-mediated IL-1β and IL-18 release from monocytes
(Sluyter et al., 2004a, Sluyter et al., 2004b), mycobacterial and toxoplasma
killing within macrophages (Fernando et al., 2007, Lees et al., 2010) and
apoptosis of macrophages and lymphocytes (Fernando et al., 2005, Wiley et al.,
2002). Glu496Ala has been associated with increased susceptibility to
extrapulmonary tuberculosis (Fernando et al., 2007). Recently, Glu496Ala was
linked to decreased risk of ischemic heart disease in smokers (Gidlöf et al.,
2012). Other loss-of-function SNPs include the null allele (rs35933842),
Arg270His (rs7958311), Arg307Gln (rs28360457), Thr357Ser (ra2230912) and
Ile568Asn (rs1653624), and are also known to impair P2X7-mediated apoptosis
and killing of intracellular pathogens (Sluyter and Stokes, 2011).
Gain-of-function

SNPs

include

His155Tyr

(rs208294)

and

Ala348Thr

(rs1718119) and result in increased P2X7-mediated IL-1β release from
monocytes (Stokes et al., 2010). A recent study showed an association between
the valine residue at position 76 (rs175225809) and predisposition to multiple
sclerosis (Oyanguren-Desez et al., 2011). Moreover, Gln460Arg (rs2230912) has
been associated with the mood disorder bipolar disease (Barden et al., 2006),
and although this SNP itself does not alter P2X7 function, association with this
SNP to the gain-of-function variants Arg270 and 155Tyr suggests a possible
link of these SNPs with this disease (Sluyter et al., 2010).
Although several of the non-synonymous SNPs have been characterised
phenotypically, the exact mechanism by which human P2X7 function is altered
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is largely unknown. The Arg307Gln (rs28360457) SNP in the extracellular loop
is thought to decrease the sensitivity to ATP by removing the positive residue
from the ATP-binding site (Fig. 1.8) (Gu et al., 2004). In contrast, the Ile568Asn
(rs1653624) SNP located at the C-terminus prevents P2X7 trafficking to the cell
surface (Wiley et al., 2003), while the Ala348Thr SNP within the second
transmembrane domain is thought to result in altered gating properties (Stokes
et al., 2010).

Figure

1.8:

Schematic

representation

of

selected

single

nucleotide

polymorphisms (SNPs) in the primary sequence of the human P2X7 receptor.
Loss-of-function and gain-of-function SNPs are identified by colour (red and green
respectively). Adapted from Wiley et al. (2011).
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Table 1.4: Single nucleotide polymorphisms of the human P2RX7 gene
characterised for phenotype. dbSNP ID (rs #) are obtained from National Centre for
Biotechnology Information (http://www.ncbi.nlm.nih.gov/projects/SNP). Adapted from
Wiley et al. (2011).

dbSNP ID

Amino Acid Change

Effect on function

rs35933842

Null Allele

LoF

rs17525809

Val76Ala

Partial LoF

rs28360445

Arg117Trp

LoF

rs28360447

Gly150Arg

LoF

rs208294

His155Tyr

GoF

rs28360451

Glu186Lys

LoF

rs112631221

Asn187Lys

Possible LoF

rs28360452

Leu191Pro

Partial LoF

rs7958311

Arg270His

Partial LoF

rs7958316

Arg276His

LoF

rs28360457

Arg307Gln

rs1718119

Ala348Thr

rs2230911

Thr357Ser

LoF; associated with accelerated lumbar spine
bone loss and risk of hip arthroplasty failure
GoF; associated with anxiety disorder and
protection against toxoplasmosis
Partial LoF; decreased in vitro killing of
M. bovis by infected macrophages

rs2230912

Gln460Arg

Neutral effect; association with mood disorders

rs3751143

Glu496Ala

LoF; decreased in vitro killing of Mycobacterium
ssp and T. gondii. Association with tuberculosis
suseptibiity and risk of bone fracture

rs2230913

His521Gln

Neutral effect

rs1653624

Ile568Asn

LoF; Associated with risk of bone fracture

Abbrevations: LoF; Loss-of-function, GoF; Gain-of-function.

SNPs in the P2RX7 gene have also been found in other species. Various
laboratory mouse strains were shown to contain a Pro451Leu (rs48804829)
mutation located in the C-terminal domain (Adriouch et al., 2002). Receptors
containing this SNP are less sensitive to ATP and demonstrate severely
impaired P2X7 pore-formation, similar to the Glu496Ala SNP in the human
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P2RX7 gene (Adriouch et al., 2002, Young et al., 2006). Three additional nonsynonymous SNPs have been identified in mouse cDNA cloned by Aldrich et al.
(2002) from C57BL/6 and Balb/c mice compared to the sequence reported
originally from NTW8 microglial cells (Chessell et al., 1998). However, only one
of these, the Met283Thr SNP, appears to alter P2X7 function. The study by
Young et al. (2006) showed that the presence of a methionine residue at
position 283 significantly reduced channel currents and eliminated ethidium+
uptake. In addition, four non-synonymous SNPs have been reported online:
Gly113Asp (rs37541158); Pro396Arg (rs37237164); Arg486His (rs36331015);
and His514Arg (rs36859091) (www.ensembl.org).
With the exception of Phe103Leu (rs23314713) in the canine P2RX7 gene
(section 1.5.1) SNPs in the P2RX7 gene of other species have not been
published. One other non-synonymous SNP in the canine P2RX7 gene however
has

been

reported

online,

Pro452Ser

(rs23315462)

(www.ensembl.org).

Whether these variants alter canine P2X7 function remains unknown. Of note,
a recently identified SNP in a different P2 receptor, the P2Y12 receptor, has
been associated with postoperative haemorrhage in Greater Swiss Mountain
dogs (Boudreaux and Martin, 2011). This study, together with the association
between SNPs in the P2RX7 gene and human disorders, may support a role for
variations in the P2RX7 gene in canine disorders.

1.10 Dog as a model for human disease
Approximately 400 inherited disorders have been characterised in dogs, most
of which are relevant to humans. Dogs may provide ideal models of human
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diseases due to factors such as five- to eight-fold faster aging compared to
humans, shared environment with their owners, high level of health care
provided and that they are usually kept until old age. The selective breeding of
dogs has caused a reduced genetic variation, making genomic mapping of
diseases notably simpler (Rowell et al., 2011). A range of studies related to
human disorders have made use of dog models. Several studies used dog as a
model for Alzheimer’s disease (Butterfield et al., 2012, Barone et al., 2012,
Head et al., 2012), one of which used aged canine brain to study early amyloidβ plaque formation (Cummings et al., 1993). Dog models have also been used
for studying childhood blindness (Acland et al., 2001), type 2 diabetes (Jeong et
al., 2012), collagen type III glomerulopathy (Rortveit et al., 2012), chronic
hepatitis and fibrosis (Favier et al., 2012), cancer (Rowell et al., 2011),
Parkinson’s disease (Choi et al., 2011), muscular dystrophy (Wadosky et al.,
2011), Hurler syndrome (Shull et al., 1994) and osteoarthritis (McDevitt et al.,
1977). These studies highlight the potential of using the dog as a model for
P2X7-related disorders.

1.10.1 The native canine P2X7 receptor
Parker and Snow (1972) demonstrated 40 years ago that extracellular ATP
increased the permeability for cations in dog erythrocytes. Some three decades
later, the canine genome project revealed the gene encoding P2RX7 in domestic
dogs (Lindblad-Toh et al., 2005). Shortly after, P2X7 mRNA was identified in
the canine brain, confirming the presence of P2X7 within the domestic dog (Lee
et al., 2005). A more recent study using blood from English Springer Spaniels
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showed that P2X7 was responsible for the ATP-induced cation flux in
erythrocytes (Sluyter et al., 2007). Similar to human P2X7, BzATP was a
complete agonist of canine P2X7 compared to ATP. Canine P2X7 was also
shown to be sensitive to 2-meSATP and ATPγS, although the agonist potencies
were lower than for BzATP and ATP (Sluyter et al., 2007). ATP-induced
ethidium+ uptake into English Springer Spaniel erythrocytes and lymphocytes
was 40- and five-fold greater compared to equivalent human cell types
(Stevenson et al., 2009). In contrast, ATP-induced ethidium+ uptake into canine
monocytes was three-fold lower compared to human monocytes (Sluyter et al.,
2007). Comparison of dog and human erythrocytes suggested that this
difference in P2X7 function was directly due to differences in P2X7 expression
(Sluyter et al., 2007).
Recently, our group cloned canine P2X7 from an English Springer Spaniel in
order to further characterise the receptor pharmacologically (Jalilian, 2011).
Moreover, our laboratory confirmed the presence of functional P2X7 in canine
monocytes, and B- and T-lymphocytes by an ATP-induced YO-PRO-12+ uptake
assay (Jalilian, 2011). The ATP-induced YO-PRO-12+ uptake into canine
monocytes was impaired by the P2X7 antagonists A438079 and KN-62,
indicating that the dye uptake is attributed to P2X7 (Jalilian, 2011). Similar to
the previously studied English Springer Spaniel breed (Stevenson et al., 2009)
the relative P2X7 function in T-lymphocytes was higher compared to Blymphocytes and monocytes from five different dog breeds (Jalilian, 2011).
Moreover, ATP-induced YO-PRO-12+ uptake into canine monocytes was
determined in 43 dogs of various pure and cross breeds. The relative P2X7
function of monocytes varied between and within dog breeds (Peranec, 2011,
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Jalilian, 2011). The cause of this variation was not determined but it is
possible that SNPs in the canine P2RX7 gene may be responsible for variation
in canine P2X7 function. In addition, LPS-primed canine monocytes were
shown to express P2X7, TLR4, NALP3, caspase-1, IL-1β and IL-18 mRNA
(Jalilian, 2011), and that P2X7 activation could induce IL-1β release from these
cells (Peranec, 2011). Functional P2X7 was also identified in the Madin-Darby
canine kidney (MDCK) cell line (Jalilian, 2011). However, the expression was
relatively low, with functional responses only observed in sucrose medium
which is known to potentiate P2X7-mediated responses (Michel et al., 1999,
Gadeock et al., 2012). MDCK cells were also shown to express TLR4, NALP3
and caspase-1; IL-1β and IL-18 however were not detected (Jalilian, 2011).

1.11 Aims
This thesis forms a part of an ongoing study investigating the role of canine
P2X7 in inflammation and immunity. Specifically, this thesis aims to:
1. Confirm the presence or absence of P2X7 and NALP3-related components
in LPS-primed canine monocytes and MDCK cells (Chapter 2);
2. Determine if ATP or TLR ligands induce IL-1β release from MDCK cells
and in whole canine blood (Chapter 2);
3. Sequence and pharmacologically characterise a recombinant canine
P2X7 receptor cloned from an English Springer Spaniel (Chapter 3);
4. Confirm if the relative monocyte P2X7 function varies between dogs and
to determine if this variation is due to SNPs in the P2RX7 gene.
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Chapter 2: P2X7 and IL-1β release in canine monocytes and
kidney cells

2.1 Materials and Methods
2.1.1 Materials
RPMI-1640 medium, Dulbecco’s modified Eagle’s/F12 (DMEM/F12) medium,
L-glutamine, GlutaMAX, YO-PRO-12+ and 0.25% trypsin were from Invitrogen
Corporation (Auckland, New Zealand). Foetal calf serum (FCS) was from
Bovogen (East Keilor, Australia). Penicillin-streptomycin, ethidium bromide,
lipopolysaccharide (LPS) from Escherichia coli serotype 055:B5, adenosine 5’triphosphate (ATP), nigericin, 100% ethanol and MgCl2 were from Sigma
Chemical Company (St Louis, MO). Ficoll-Paque PLUS and ExoSAP-IT PCR
Clean-up Kit were from GE Healthcare (Uppsala, Sweden). Primers were from
Geneworks (Hindmarsh, Australia). BigDye® Terminator V3 was from Applied
Biosystems (Carlsbad, CA). Agarose was from Bioline (Alexandria, Australia).
AZ10606120 was obtained from Tocris Bioscience (Ellisville, MO). Lipoteichoic
acid (LTA) from Staphylococcus aureus was from Invivogen (San Diego, CA).
Bovine serum albumin (BSA), ethylenediaminetetraacetic acid (EDTA), Tris
base and other general grade chemicals were from Amresco (Solon, OH).

2.1.2 Cell lines
Madin-Darby canine kidney (MDCK) epithelial cells were purchased from the
European Collection of Cell Cultures (Porton Down, UK). Cells were cultured in
DMEM/F12 medium supplemented with 10% FCS, 2 mM GlutaMAX, 100
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units/mL penicillin and 10 µg/mL streptomycin (complete MDCK medium).
Cells were incubated at 37°C/5% CO2 and were passaged two times per week
by limited trypsinisation, as required.

2.1.3 Collection of dog blood
Peripheral blood from 9 mixed or pure breed dogs was collected into vacutainer
tubes containing lithium heparin (Greiner Bio-One, Frickenhausen, Germany),
from either Albion Park Veterinary Hospital (Albion Park, Australia) or Oak
Flats Veterinary Clinic (Oak Flats, Australia). Written consent was obtained
from informed owners with approval by the University of Wollongong animal
ethics committee.

2.1.4 LPS-primed canine peripheral blood monoytes
Blood was centrifuged (450 x g for 15 min; with brake off) and the buffy coat
was collected. Buffy coats were diluted with RPMI-1640 medium, underlaid
with Ficoll-Paque PLUS and centrifuged (560 x g for 20 min; with brake off).
The peripheral blood mononuclear cells (PBMCs) were collected and washed
once with RPMI-1640 medium (450 x g for 10 min followed by 300 x g for 5
min) and twice with RPMI-1640 medium (300 x g for 5 min). PBMCs were then
suspended in 20 mL RPMI-1640 medium containing 10% FCS and 5 mM Lglutamine (complete monocyte medium) and cultured in a T75 flask (Greiner
Bio-One, Germany) for 2 hours at 37ºC/5% CO2. Non-adherent mononuclear
cells were removed by swirling the flask six times and removing the medium.
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This process was repeated using 10 mL RPMI-1640 medium to remove the
remaining non-adherent cells. The cells were then incubated in 20 mL
complete monocyte medium containing 0.1 µg/mL LPS for 4 hours at 37ºC/5%
CO2.

2.1.5 Detection of P2X7 and NALP3-related components
Total RNA was isolated from LPS-primed monocytes or MDCK cells using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
instructions. Equal amounts of RNA for each cell type were amplified by
reverse transcription (RT)-PCR using the MyTaq One-Step RT-PCR Kit (Bioline,
Sydney Australia) using primer pairs specific for various canine mRNA
transcripts (Table 2.1). Each RT-PCR reaction contained 2X MyTaq One-Step
mix, reverse transcriptase, 2 U RiboSafe RNase Inhibitor, 0.2 µM forward and
reverse primer, 1-2 µg RNA template and DEPC-treated H2O to a final volume
of 12 µL. The RT-PCR was performed using a Mastercycler Pro S thermocycler
(Eppendorf, Germany) using the cycle conditions described in Table 2.1. The
amplicons were then separated via electrophoresis using a 1.5% agarose gel at
100 V for 1 hour in Tris acetate-EDTA (TAE) buffer (20 mM acetic acid, 1 mM
EDTA, 40 mM Tris, pH 8) and stained with ethidium bromide.

2.1.6 Sequencing of P2X7 and NALP3-related components
Amplicons from RT-PCR (section 2.1.5) were purified using 1 µL of diluted (1:4)
ExoSAP-IT enzyme per 2.5 µL of cDNA, and the samples were incubated using
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a Mastercycler Pro S thermocycler at 37ºC for 15 min, and then 80ºC for 15
min. Each sequencing reaction contained 3.4 µL sequencing buffer, 1 µL
BigDye® Terminator v3.1, 1 µL cDNA, 0.6 µM forward or reverse primer (Table
2.1) and sterile deionised H2O to a final volume of 20 µL. PCR amplification was
then performed using a Mastercycler Pro S thermocycler with 30 repeats of
denaturation at 96ºC for 30 sec, annealing at 55ºC for 15 sec and extension at
60ºC for 4 min, followed by a single cycle of final extension at 30ºC for 30 sec.
Table 2.1: Primers and cycle conditions for P2X7 and NALP3-related components
a

b

Product
size (bp)

Primer

Forward primer 5’-3’

Reverse primer 5’-3’

Cycle conditions

TLR4

GTCTGGCTGGCTTAAAGATC

CTGCAATCTAGGATCTGGAG

95°C for 20 s,
52.4°C for 20 s,
72°C for 60 s

910

P2X7

TGCCTCCCATCCCAGCTCCC

GTCCTGGGAGCCAAAGCGCC

95°C for 10 s,
62°C for 10 s,
72°C for 30 s

240

NALP3

CACTGTCAGCCTTTGGCAGGGT

GTCTCCCAGGGCGTTGTGGC

95°C for 10 s,
63.7°C for 10 s,
72°C for 30 s

273

Caspase-1

ACAGACGCTGGGGCTCTCCT

CCCAGGCCCTCCAGCAGACT

95°C for 10 s,
63.7°C for 10 s,
72°C for 30 s

339

IL-1β

TGCAAAACAGATGCGGATAA

GTAACTTGCAGTCCACCGATT

95°C for 10 s,
53°C for 10 s,
72°C for 30 s

64

IL-18

CCTGGAATCAGATTACTTTGGC

GTTTTGTTCTTACAGGAGAGAG

95°C for 10 s,
57°C for 10 s,
72°C for 30 s

251

aPrimers

for

P2X7

(Accession

no:

NM_001113456.1),

NALP3

(Accession

no:

XM_843284.2) and caspase-1 (Accession no: NM_001003125.1) were designed from
the corresponding reference sequences (http://www.ncbi.nlm.nih.gov) using Primer 3
(http://frodo.wi.mit.edu/ primer3/). Primers for TLR4 (Asahina et al., 2003), IL-1β
(Maccoux et al., 2007) and IL-18 (Chamizo et al., 2001) were obtained from previous
publications.
bPCR

mixtures were incubated at 45°C for 20 min (except TLR4 which was incubated

for 30 min), then at 95°C for 60 sec (s), followed by 42 cycles as indicated, and then a
final extension at 72°C for 5 min.
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To purify PCR products, amplicons were mixed with 2 µL 125 mM EDTA (pH 8),
2 µL sodium acetate (pH 5.1) and 50 µL 100% ethanol. The mix was then
incubated at room temperature for 15 min followed by centrifugation (13200 x
g for 15 min). The precipitated products were then washed with ice-cold 70%
ethanol (13200 x g for 15 min) and dried using a heat block at 60ºC. All
products were kindly sequenced using a 3130xl capillary sequencer (Applied
Biosystems, Carlsbad, CA) by Margaret Phillips (University of Wollongong,
Australia). Resulting sequences were compared to the corresponding NCBI
(http://www.ncbi.nlm.nih.gov)

reference

sequences

using

Geneious

Pro

Software (Biomatters, Auckland, New Zealand).

2.1.7 IL-1β release from MDCK cells
MDCK cells were seeded in 24-well plates (Greiner Bio-One) at 2 x 105
cells/well and incubated overnight at 37oC/5% CO2. Cells were then incubated
with fresh complete MDCK medium in the absence or presence of LPS (as
indicated) (1 mL/well) for 24 hours at 37oC/5% CO2. Alternatively, MDCK cells
were seeded in 24-well plates at 1 x 105 cells/well and incubated overnight at
37oC/5% CO2. Cells were then incubated with fresh complete MDCK medium
in the absence or presence of 10

g/ml LPS for 4 or 24 hours. These cells were

then pre-incubated in RPMI-1640 medium (containing 0.1% BSA) or in sucrose
medium (280 mM sucrose, 5 mM KCL, 10 mM N-methyl-D-glucamine, 5 mM
glucose, 10 mM HEPES, 0.1% BSA, 2 mM Ca2+, 1 mM Mg2+, pH 7.4) (0.3
ml/well) at 37oC/5% CO2 for 15 min, followed by 60 min incubation in the
absence or presence of 3 or 5 mM ATP or 20

M nigericin. Following
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incubations, samples were centrifuged (11,000 x g for 30 sec), and cell-free
supernatants collected and stored at -80oC until required. The amount of IL-1β
in cell-free supernatants was quantified using a Canine IL-1β VetSetTM ELISA
Development Kit (Kingfisher Biotech, St. Paul, MN) according to the
manufacturer's instructions and measured at 450 nm on a Spectramax Plus
384 spectrophotometer (Molecular Devices, Sunnyvale, CA).

2.1.8 ATP-induced IL-1β release from LPS- or LTA-primed canine whole
blood
Whole blood (100 µL) was plated in 96-well plates (Greiner Bio-One). Equal
volumes of RPMI-1640 medium (supplemented with 2 mM GlutaMAX, 100
units/mL penicillin and 10 µg/mL streptomycin; incomplete culture medium)
were added to each well and sterile H2O was added to surrounding wells. The
diluted blood was then incubated in the absence or presence of 100 ng/mL LPS
or LTA for 2 hours at 37oC/5% CO2. In some experiments 1 µM AZ10606120
was added after 1 hour and 45 min incubation with LPS or LTA. The blood was
then co-incubated in the absence or presence of 6 mM ATP for a further 30 min
or 2 hours at 37oC/5% CO2. Following incubations, plates were centrifuged
(700 x g for 10 min), and cell-free supernatants collected and stored at -80oC
until required. The amount of IL-1β in cell-free supernatants was quantified as
described in section 2.1.7.
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2.1.9 IL-1β release from LPS- or LTA-primed canine whole blood
Whole blood was plated in 96-well plates and diluted with equal volumes of
incomplete culture medium as described in section 2.1.8. The diluted blood
was then incubated in the absence or presence of LPS or LTA (as indicated) for
24 hours at 37oC/5% CO2. In some experiments diluted blood was also
incubated in the absence or presence of 1 µM AZ10606120 for 24 hours at
37oC/5% CO2. Following incubations, plates were centrifuged (700 x g for 10
min) and cell-free supernatants collected and stored at -80oC until required.
The amount of IL-1β in cell-free supernatants was quantified as described in
section 2.1.7.

2.1.10 Presentation of data and statistical analysis
Results are expressed as mean ± standard deviation (SD). All graphs were
prepared using GraphPad Prism 5 (GraphPad Software, Inc. La Jolla, CA).
Differences between each treatment were compared using ANOVA for multiple
comparisons (with Tukey’s post hoc test) using GraphPad Prism 5 software
with P < 0.05 considered significant.
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2.2 Results
2.2.1 Canine monocytes and MDCK cells express TLR4, P2X7, NALP3,
caspase-1, IL-1β and IL-18
Our group has previously shown that MDCK cells contain TLR4, P2X7, NALP3
and caspase-1 mRNA. In contrast, mRNA of the pro-inflammatory cytokines IL1β and IL-18 were not detected (Jalilian, 2011). These experiments however did
not include a positive control, such as LPS-primed canine monocytes, therefore
the absence of IL-1β and IL-18 in MDCK cells remains in doubt. Moreover,
although the RT-PCR products corresponded to the predicted size of each
transcript in canine monocytes and MDCK cells (Jalilian, 2011), sequencing of
these amplicons is required to confirm the identity of each transcript. RT-PCR
was used to confirm if canine monocytes and MDCK cells express P2X7, NALP3
and caspase-1, and if canine monocytes express IL-1β and IL-18 and determine
if MDCK cells express IL-1β and IL-18. Since MDCK cells express TLR4 mRNA
and cell-surface TLR4 (Jalilian, 2011), this molecule was also included as a
positive control. Sufficient cDNA was not available to test the expression of
TLR4 in monocytes. However these cells have previously been shown to express
this molecule (Jalilian, 2011). As expected MDCK cells expressed TLR4 mRNA
(Fig. 2.1). Both MDCK cells and LPS-primed canine monocytes expressed P2X7,
NALP3, caspase-1, IL-1β and IL-18 mRNA (Fig. 2.1), with transcripts
corresponding to the predicted size for each molecule (Table 2.1).
The identity of each above transcript, except IL-1β due to its small size (64 bp),
was then confirmed by sequencing. The nucleobase sequences deduced from
the TLR4 (accession no: NM_001002950.2; Fig. 2.2), P2X7 (accession no:
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NM_001113456.1; Fig. 2.3), NALP3 (accession no: XM_843284.2; Fig. 2.4) and
IL-18 (accession no: NM_001003169.1; Fig. 2.6) amplicons were 100% identical
to the corresponding reference sequence. The nucleobase sequence deduced
from the caspase-1 amplicon was 99% identical to the reference sequence
(accession no: NP_001003125.1; Fig. 2.5).
MDCK Monocytes
TLR4
P2X7
NALP3
Caspase-1
IL-1β
IL-18

Figure 2.1: MDCK cells express TLR4, P2X7, NALP3, caspase-1, IL-1β and IL-18
mRNA. RNA was isolated from MDCK cells and LPS-primed canine monocytes
(positive control) and TLR4, P2X7, NALP3, caspase-1, IL-1β and IL-18 were amplified
using RT-PCR. Products were separated by agarose gel electrophoresis and stained
with ethidium bromide. Results are representative of at least 2 experiments.

Figure 2.2: Partial sequence of canine TLR4. Amplicons of TLR4 from MDCK cells
from Fig. 2.1 were sequenced. The deduced nucleobase sequence was compared to the
NCBI reference sequence (accession no: NM_001002950.2).
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Figure 2.3: Partial sequence of canine P2X7. Amplicons of P2X7 from LPS-primed
canine monocytes and MDCK cells from Fig. 2.1 were sequenced. The deduced
nucleobase sequence was compared to the NCBI reference sequence (accession no:
NM_001113456.1).

Figure 2.4: Partial sequence of canine NALP3. Amplicons of NALP3 from LPSprimed canine monocytes and MDCK cells from Fig. 2.1 were sequenced. The deduced
nucleobase sequence was compared to the NCBI reference sequence (accession no:
XM_843284.2).
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Figure 2.5: Partial sequence of canine caspase-1. Amplicons of caspase-1 from LPSprimed canine monocytes and MDCK cells from Fig. 2.1 were sequenced. The deduced
nucleobase sequence was compared to the NCBI reference sequence (accession no:
NP_001003125.1).

Figure 2.6: Partial sequence of canine IL-18. Amlicons of IL-18 mRNA from LPSprimed canine monocytes and MDCK cells from Fig 2.1 were sequenced. The deduced
nucleobase sequence was compared to the NCBI reference sequence (accession no:
NM_001003169.1).

2.2.2 IL-1β release could not be detected from MDCK cells
To determine if MDCK cells release IL-1β, cells were first incubated in the
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absence or presence of 0.1, 1 or 10 µg/mL LPS for 24 hours, and IL-1β in cellfree supernatants was measured using a canine IL-1β ELISA. Cells incubated
in the absence of LPS for 24 hours failed to release IL-1β (0 ± 0 pg/mL; n = 3).
Similarly LPS at all concentrations failed to induce detectable IL-1β release
from these cells (0 ± 0 pg/mL; n = 3). Next, unprimed MDCK cells or cells
primed with 10

g/ml LPS for 4 or 24 hours (in RPMI-1640 or sucrose

medium) were incubated with 3 mM ATP, 5 mM ATP or 20

M nigericin, which

induces IL-1β release from human monocytes independently of P2X7 (Sluyter
et al., 2004b), for 60 min, and IL-1β in cell-free supernatants was measured by
ELISA. None of these conditions induced detectable IL-1β release from MDCK
cells (Table 2.2).

Table 2.2: ATP and nigericin do not induce IL-1β release from LPS-primed MDCK
cells. Unprimed MDCK cells (Nil) or MDCK cells in complete MDCK medium
containing 10

g/mL LPS were incubated at 37oC for 4 or 24 hours. Cells were then

incubated in RPMI-1640 medium (containing 0.1% BSA) or sucrose medium in the
absence (Control) or presence of 3 or 5 mM ATP, or 20

M nigericin at 37oC for 60

min. The amount of IL-1β in cell-free supernatants was quantified using a canine IL1β ELISA (n = 3).

LPS
Priming

Assay
Medium

Nil

IL-1β (pg/mL)

RPMI-1640

Control
0±0

3 mM ATP
0±0

5 mM ATP
0±0

20 M Nigericin
0±0

4h

RPMI-1640

0±0

0±0

0±0

0±0

24 h

RPMI-1640

0±0

0±0

0±0

0±0

24 h

Sucrose

0±0

0±0

0±0

0±0
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2.2.3 ATP-induced IL-1β release in canine whole blood requires priming
with LPS
Our laboratory has previously shown that ATP induces IL-1β release from LPSprimed monocytes (Peranec, 2011) and has previously used a whole blood
assay to measure human IL-1β release (Sluyter et al., 2004b). Therefore this
whole blood assay was used to determine if priming with LPS or LTA induces
canine IL-1β release. Peripheral blood from three dog breeds was incubated
with 100 ng/mL LPS or LTA for 2 hours followed by incubation in the absence
or presence of ATP for 30 min or 2 hours. IL-1β release in cell-free
supernatants was measured by ELISA. Incubation of blood for 2.5 or 4 hours
in the absence of TLR ligand and ATP resulted in IL-1β release from only one of
three dogs (Fig. 2.7). Similar results were observed for samples incubated in
the presence of LTA or ATP alone (at both 2.5 and 4 hours). In contrast,
incubation with LPS alone induced IL-1β release from two of three dogs (at 2.5
hours) and from all three dogs (at 4 hours), however this increase failed to
reach statistical significance. Incubation with ATP for 30 min or 2 hours
caused a five-fold and significant increase in IL-1β release from LPS-primed
blood compared to LPS-primed blood incubated in the absence of ATP (Fig.
2.7). Of note, the amount of ATP-induced IL-1β release varied between dogs,
each of which were a different breed (Fig. 2.7). In contrast, ATP did not induce
any further IL-1β release from LTA-primed blood compared to LTA-primed
blood incubated in the absence of ATP (Fig. 2.7).
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Figure 2.7: Priming with LPS but not LTA mediates ATP-induced IL-1β release
from canine whole blood. (A,B) Whole blood in incomplete culture medium was
incubated in the absence (Nil) or presence of 100 ng/mL LPS or LTA for 2 hours at
37oC/5% CO2 and then in the absence or presence of 6 mM ATP for (A) 30 min or (B)
2 hours at 37oC/5% CO2. (A,B) Incubations were stopped by centrifugation and the
amount of IL-1β in cell-free supernatants was quantified by ELISA. * P < 0.05
compared to nil and ATP alone.

2.2.4 LPS induces IL-1β release in canine whole blood
To determine if stimulation with LPS or LTA can induce IL-1β release from
canine whole blood in the absence of exogenous ATP, canine whole blood was
incubated in the absence (control) or presence of 0.01, 0.1, 1 or 10 µg/mL LPS
or LTA from 24 hours, and IL-1β release in cell-free supernatant was measured
by ELISA. Incubation of blood for 24 hours in the absence of TLR ligands
resulted in IL-1β release from one of three dogs (Fig. 2.8). LTA had no effect on
IL-1β release from canine whole blood compared to blood incubated in the
absence of TLR ligands (control) (Fig. 2.8). In contrast, LPS induced IL-1β
release from canine whole blood at all concentrations compared to control (Fig.
50

2.8). A five-fold average increase in IL-1β release was found at 0.01 and 0.1
µg/mL LPS compared to control. At incubations with 1 or 10 µg/mL LPS, the
IL-1β concentrations were six- and eight-fold higher, respectively, compared to
control. As for ATP-induced IL-1β release (Fig. 2.7), LPS-induced IL-1β release
varied between dog breeds (Fig. 2.8).
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Figure 2.8: Stimulation with LPS but not LTA induces IL-1β release from canine
whole blood. Whole blood in incomplete culture medium was incubated in the
absence (Nil) or presence of varying concentrations of LPS or LTA (as indicated) for 24
hours at 37oC/5% CO2. Incubations were stopped by centrifugation and the amount
of IL-1β in cell-free supernatants was quantified by ELISA. ** P < 0.01 compared to
nil.

2.2.5 AZ10606120 failed to impair ATP-induced IL-1β release in canine
whole blood
To determine if the ATP-induced IL-1β release from LPS-primed canine whole
blood was due to P2X7 activation, LPS-primed canine whole blood was
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incubated in the absence or presence of 1 µM AZ10606120, followed by
incubation in the absence or presence of 6 mM ATP for 30 min. As above (Fig.
2.7), ATP induced significant IL-1β release from LPS-primed blood compared to
LPS-primed blood incubated in the absence of ATP (Fig. 2.9). Of note,
incubation with AZ10606120 did not alter the amount of IL-1β release in the
presence of ATP compared to blood incubated in the presence of ATP alone (Fig.
2.9). In the presence of AZ10606120 ATP-induced IL-1β release however failed
to reach significance compared to IL-1β release in the presence of AZ10606120
alone. This was most likely due do the variation in IL-1β release from Labrador
3. IL-1β release in the absence or presence of AZ10606120 (in the absence or
presence of ATP) was similar (Fig. 2.9).
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Figure 2.9: AZ10606120 does not impair ATP-induced IL-1β release in LPSprimed canine whole blood. Whole blood in incomplete culture medium was
incubated with 100 ng/mL LPS for 2 hours at 37oC/5% CO2, with 1 µM AZ10606120
(AZ10) added in the final 15 min as indicated. Samples were then incubated for a
further 30 min at 37oC/5% CO2 in the absence or presence of 6 mM ATP. Incubations
were stopped by centrifugation and the amount of IL-1β in cell-free supernatants was
quantified by ELISA. * P < 0.05 compared to nil.
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2.2.6 AZ10606120 failed to impair LPS-induced IL-1β release in canine
whole blood
To determine if the LPS-induced IL-1β release from canine whole blood was due
to P2X7 activation, canine whole blood was co-incubated in the absence or
presence of 10 µg/mL LPS and in the absence or presence of 1 µM AZ10606120
for 24 hours. As above (Fig. 2.8), LPS induced IL-1β release in blood compared
to blood incubated in the absence of LPS however this failed to reach
significance (Fig. 2.10). Moreover, co-incubation with AZ10606120 did not alter
LPS-induced IL-1β release (Fig. 2.10). IL-1β release in the absence or presence
of AZ10606120 (in the absence of LPS) was similar (Fig. 2.9).
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Figure 2.10: AZ10606120 does not impair LPS-induced IL-1β release from canine
whole blood. Whole blood in incomplete culture medium was incubated with in the
absence (Nil) or presence of 10 µg/mL LPS and in the absence or presence of 1 µM
AZ10606120 (AZ10) for 24 hours at 37oC/5% CO2. Incubations were stopped by
centrifugation and the amount of IL-1β in cell-free supernatants was quantified by
ELISA.
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2.3 Discussion
The current study confirms the expression of P2X7 and NALP3-related
components in canine monocytes as previously observed by Jalilian (2011).
Expression of P2X7, NALP3, caspase-1, IL-1β and IL-18 mRNA was identified
by RT-PCR with amplicons corresponding to the predicted size and the identity
of each confirmed by sequencing (Fig 2.1 and 2.3-6). Our laboratory recently
showed that ATP induces IL-1β release from LPS-primed canine monocytes via
activation of the P2X7 receptor (Peranec, 2011). P2X7-induced IL-1β release
from LPS-primed canine monocytes however varied between dogs (Peranec,
2011). Therefore, due to this variation, IL-1β release was examined in a whole
blood assay as previously used by our group (Sluyter et al., 2004b). This assay
is simpler to perform and contain less experimental manipulations. Thus, this
method is potentially less prone to experimental variation. The current study
demonstrated that ATP also induces IL-1β release in LPS-primed canine whole
blood (Fig. 2.7 and 2.9). As for LPS-primed monocytes (Peranec, 2011), ATPinduced IL-1β release in LPS-primed blood varied between dogs. In contrast to
LPS-primed monocytes however, a role for P2X7 in ATP-induced IL-1β release
in LPS-primed blood could not be established, as 1 µM AZ10606120 failed to
impair IL-1β release (Fig. 2.9). This result was unexpected as AZ10606120, as
well as other P2X7 antagonists, have been shown to impair 2 mM ATP-induced
IL-1β release in LPS-primed canine whole blood (Roman et al., 2009). However,
this prior study demonstrated that the sensitivity for AZ10606120 decreases in
IL-1β release assays with whole blood compared to ethidium+ uptake assays
with cells in HEPES-buffered saline solutions (Roman et al., 2009). Thus, it is
likely that higher concentrations of AZ10606120 are required to impair IL-1β
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release from LPS-primed canine whole blood, however due to time constraints
this was not examined. Alternatively, the batch of AZ10606120 used in the
current study may have expired. Unfortunately no other aliquots of this
compound were available for further testing. New AZ10606120 and additional
P2X7 antagonists should be examined in the future to determine if P2X7 is
responsible for ATP-induced IL-1β release in LPS-primed canine whole blood.
Stimulation with LPS has been shown to induce IL-1β release in human whole
blood (Van Der Poll and Lowry, 1997). The current study demonstrated that
LPS also induces IL-1β release in canine whole blood in the absence of
exogenous ATP (Fig. 2.8 and 2.10). As for ATP-induced IL-1β release in LPSprimed blood (Fig. 2.7 and 2.9), LPS-induced IL-1β release in whole blood
varied between dogs. Moreover, a role for P2X7 in LPS-induced IL-1β release in
whole blood could not be established, as 1 µM AZ10606120 failed to impair IL1β release (Fig. 2.10). As for ATP-induced IL-1β release in LPS-primed blood,
higher concentrations of a new batch of AZ10606120 and additional P2X7
antagonists should be examined in the future to determine if P2X7 is
responsible for LPS-induced IL-1β release in canine whole blood. However, the
possibility remains that LPS induces IL-1β release in whole blood via a
mechanism independent of P2X7.
Stimulation with LTA has also been shown to induce IL-1β release in human
whole blood (Hermann et al., 2002). In the current study LTA failed to induce
IL-1β release from canine whole blood following stimulation with ATP over 30
min or 2 hours (Fig. 2.7). Moreover, incubation with LTA over 24 hours failed to
induce IL-1β release from canine whole blood (Fig. 2.8). However, these
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findings need to be verified by using a positive control, such as examining LTAinduced IL-1β release in human whole blood to ensure the LTA stock is
working.
This study also aimed to confirm if MDCK cells express P2X7 and NALP3related components to possibly provide a model cell line to study the role of
P2X7 in kidney epithelial cells and renal disorders. Expression of TLR4, P2X7,
NALP3 and caspase-1 mRNA in MDCK cells was confirmed by RT-PCR with
amplicons corresponding to the predicted size and the identity of each
confirmed by sequencing (Fig. 2.1-5). The expression of IL-1β and IL-18 mRNA
in MDCK cells was also demonstrated by RT-PCR and sequencing (Fig. 2.1 and
2.6), contradicting a recent study in our laboratory (Jalilian, 2011). These
differences are readily explained by the absence of a positive control in the
original experiments by Jalilian (2011), suggesting that the RT-PCR of the
cytokines in this previous study failed. Prior to the current study and that of
Jalilian (2011), the expression of P2X7, NALP3, caspase-1 and IL-18 had not
been directly observed in MDCK cells, although pharmacological blockade of
caspase-1 was shown to prevent apoptosis in MDCK cells (Feldenberg et al.,
1999) indirectly supporting the presence of this enzyme in these cells. In
contrast, TLR4 and IL-1β mRNA had been demonstrated previously in MDCK
cells (Gröne et al., 2002, Sun et al., 2007).
Despite the presence of the above molecules in MDCK cells and various
attempts, IL-1β release could not be detected from these cells using a
commercially available IL-1β ELISA kit (minimum assay sensitivity of 0.053
ng/mL). MDCK cells failed to induce detectable IL-1β release following 24 hour
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incubation in the absence or presence of 0.1-10

g/ml LPS (section 2.2.2).

Moreover, neither 60 min incubation with 3 mM ATP, 5 mM ATP nor 20

M

nigericin could induce detectable IL-1β release from MDCK cells primed with
10

g/ml LPS for 4 or 24 h, or from unprimed MDCK cells (Table 2.2). The

inability of ATP to induce IL-1β from MDCK cells could not be solely attributed
to the low amount of P2X7 on MDCK cells, as nigericin, which induces human
and murine IL-1β release independently of P2X7 activation (Sluyter et al.,
2004b, Solle et al., 2001a), also failed to induce IL-1β from MDCK cells. Thus,
it is likely that IL-1β and/or other NALP3 inflammasome-associated molecules
are present at low amounts in MDCK cells, and that the LPS-priming
conditions employed in this study are insufficient to activate or up-regulate
these molecules to cause detectable IL-1β release. Moreover, it is possible that
other components responsible for the release of IL-1β are absent in MDCK
cells.
The presence of NALP3 in MDCK cells is noteworthy. Recent evidence using
knockout

mice

indicates

that

kidney

epithelial-expressed

NALP3,

independently of inflammasome activation and cytokine release, mediates the
inflammation and associated tissue damage during renal ischemia/reperfusion
injury (Shigeoka et al., 2010). Whether the autocrine release of ATP and
subsequent activation of P2X7 is involved in this process in vivo remains
unknown, however MDCK cells can release ATP following mechanical
stimulation (Ostrom et al., 2000). Thus these cells may serve as a suitable
model cell line to study this potential mechanism further.
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In conclusion, the current study demonstrates that P2X7 and NALP3-related
components are expressed in canine monocytes and MDCK cells. Further
studies however are required to determine whether or not MDCK cells release
IL-1β. In addition, ATP induces IL-1β release in canine whole blood and this
process requires priming with LPS. Moreover, stimulation with LPS over 24
hours induces IL-1β release in the absence of exogenous ATP. Further studies
are required, however, to determine if either or both of these processes require
P2X7 activation, or if LTA can induce IL-1β release in canine whole blood.
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Chapter 3: Genetic and pharmacological characterisation of a
recombinant canine P2X7 receptor

3.1 Materials and Methods
3.1.1 Materials
OPTI-MEM reduced serum medium and Lipofectamine 2000 were from
Invitrogen Corporation (Auckland, New Zealand). 3’-O-(4-benzoyl)benzoyl ATP
(BzATP), adenosine 5’-diphosphate (ADP), uridine 5’-triphosphate (UTP), α,βmethylene ATP (α,β-meATP), Brilliant Blue G (BBG) and propidium iodide were
purchased from Sigma Chemical Company (St Louis, MO). Primers were from
Geneworks (Hindmarsh, Australia). EDTA-free Protease Inhibitor Cocktail
Tablets were from Roche (Mannheim, Germany). Phenylmethylsulfonyl fluoride
(PMSF), n-dodecyl-β-D-maltoside, Tween-20, D-glucose and other general grade
chemicals were from Amresco (Solon, OH). Sample buffer and 4-20% TrisGlycine gel were from NuSep (Lane Cove, Australia). Rabbit anti-rat P2X7
(intracellular epitope) polyclonal Antibody (pAb) and rabbit anti-mouse P2X7
(extracellular epitope) pAb were purchased from Alomone labs (Jerusalem,
Israel). Horseradish peroxidise (HRP)-conjugated goat anti-rabbit IgG pAb was
from Rockland Immunochemicals Inc. (Gilbertsville, PA). Precision Plus Protein
Standards, nitrocellulose membrane and Precision StrepTactin-(HRP) conjugate
were from Bio-Rad (Hercules, CA). SuperSignal West Pico Chemiluminescent
Substrate was from Pierce (Rockford, IL). Amersham Hyperfilm ECL was from
GE Healthcare (Uppsala, Sweden). Developer and fixer were from Kodak
(Rochester, NY). AZ10606120, AZ11645373 and A-438079 were obtained from
Tocris Bioscience (Ellisville, MO). Adenosine 5’-O-(3-thiotriphosphate) (ATPγS)
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and KN-62 were from Alexis Biochemicals (Lausen, Switzerland). Diploma milk
powder was from Fonterra Foodservices (Mount Waverly, Australia). cDNA of
the canine P2X7 construct (pcP2X7-Ac-N1) (Jalilian, 2011) was provided by
Iman Jalilian (University Of Wollongong, Wollongong, Australia). The remainder
of materials are described in Chapter 2.

3.1.2 Cell lines
The human embryonic kidney (HEK) 293 cell line (originally obtained from the
American Type Culture Collection, Manassas, VA) was kindly provided by Dr
Leanne Stokes (University of Sydney, Penrith, Australia). The human RPMI
8226 cell line (originally obtained from the European Collection of Cell
Cultures, Porton Down, UK) was kindly provided by Associate Professor Marie
Ranson (University of Wollongong, Wollongong, Australia). Cells were cultured
in DMEM/F12 medium supplemented with 10% foetal calf serum (FCS), 2 mM
Glutamax, 100 units/mL penicillin and 10 µg/mL streptomycin (complete
culture medium). Cells were incubated at 37°C/5% CO2 and were passaged two
times per week by limited trypsinisation (HEK 293 cells), as required.

3.1.3 Sequencing of the canine P2X7 construct
Sequencing reactions were performed as described in section 2.1.5, using the
primers described in Table 3.1. Purification of PCR products was performed as
described in section 2.1.5. Resulting sequences were compared to the NCBI
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reference sequence (Accession no: NP_001106927) using Geneious Pro
Software (Biomatters, Auckland, New Zealand).
Table 3.1: Primers used for sequencing of the canine P2X7 cDNA construct.

Primer Paira

Forward Primer 5’-3’

Reverse Primer 5’-3’

1

CCGCCTGGTGTCCCATCG

ATCTTCTTGATTCCATTCTCC

2

CCACCTCAGAGCCGTTCA

CAGCTGCATCTCCTCTG

3

TGGCACCATTAAGTGGAT

GGTTCTGAGTCTTGTGAAAGGT

4

AGACAATTGTGGAGCCAA

CTAGGTCCTGGGAGCCAAAG

aPrimers

were

designed

using

the

online

primer

design

program

Primer3

(http://frodo.wi.mit.edu/ primer3/).

3.1.4 Transfection of canine P2X7 cDNA into HEK 293 cells
HEK 293 cells were transfected with canine P2X7 cDNA as previously described
(Peranec, 2011). HEK 293 cells (0.25 - 0.5 x 106 cells/well) in complete culture
medium were incubated overnight at 37°C/5% CO2 in 6-well plates. The
following day, Lipofectamine 2000 diluted 1:20 in OPTI-MEM medium was
incubated at room temperature for 5 min. Canine P2X7 cDNA was diluted in
OPTI-MEM medium (4 µg/120 µL) and incubated as above. Equal volumes of
Lipofectamine 2000 and diluted cDNA (P2X7) or OPTI-MEM alone (mock) were
incubated at room temperature for 20 minutes prior to incubation with cells.
Complete culture medium on cells was replaced with fresh complete culture
medium, and 240 µL Lipofectamine 2000/OPTI-MEM mixtures (with or without
canine P2X7 cDNA) were added drop-wise to cells. Plates were incubated at
37°C/5% CO2 for 24 hours. The transfection medium was then removed and
replaced with fresh complete culture medium and incubated at 37°C/5% CO2
for another 24 hours.
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3.1.5 Detection of P2X7 protein by immunoblotting
Cell lysates from RPMI 8226 cells (positive control) and mock- or P2X7transfected

HEK293

cells

were

prepared

as

previously

described

(Constantinescu et al., 2010). RPMI 8226 cells were collected by centrifugation
(300 x g for 5 min) and washed three times with PBS. HEK 293 cells were
washed three times with PBS and harvested by mechanical scraping. Harvested
cells (1 x 107 cells/mL) were then incubated in lysis buffer (50 mM Bis-Tris,
750 mM 6-aminohexanoic acid, 1% n-dodecyl-β-D-maltoside, 1 mM PMSF, 1
EDTA-free protease inhibitor cocktail tablet, pH 7.0) on ice for 60 min. Cells
were sheared 10 times through a 1 mL syringe fitted with an 18 G needle and
stored at -20ºC until required. Cell lysates were thawed on ice and centrifuged
at 16,000 x g at 4ºC for 10 min. Cleared cell lysates were collected and protein
concentrations measured using a NanoDrop 2000c spectrophotometer (Thermo
Scientific, Waltham, MA) according to the manufacturer’s instructions. Cell
lysates were then incubated in NuSep reducing sample buffer containing 5%
2-mercaptoethanol at 100ºC for 5 minutes. Proteins were separated in SDS
glycine running buffer (2.4 mM Tris base, 19.2 mM Glycine, 3.5 mM SDS) by
electrophoresis using 4-20% Tris-Glycine gels (75V for 30 min, then 120V for
60 min) and transferred to nitrocellulose membrane in transfer buffer (2.5 mM
Tris base, 19.2 mM glycine, 2% methanol and deionised H2O) at 4ºC (80V for
90 min). The membrane was then washed in Tris-buffered saline containing
Tween-20 (TBST) (500 mM NaCl, 20 mM Tris, 0.2% Tween-20, pH 7.5), and
blocked in 20 mL TBST containing 5% milk powder at 4ºC overnight. The
membrane was washed three times with TBST over 30 min and then incubated
with rabbit anti-P2X7 pAb (diluted 1:500) in TBST containing 5% milk powder
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at room temperature for 2 hours. The membrane was washed as above and
incubated with HRP-conjugated goat anti-rabbit IgG antibody (diluted 1:1000)
and StrepTactin-HRP conjugate (1:5000) in TBST containing 5% milk powder
at room temperature for 1 hour. The membrane was washed as above, followed
by

incubation

with

chemiluminescent

substrate

according

to

the

manufacturer’s instructions. The membrane was visualised using Amersham
Hyperfilm ECL, following development with developer and fixer.

3.1.6 Detection of fluorescent cation uptake into transfected HEK 293
cells by fixed-time flow cytometry
Agonist-induced fluorescent cation uptake into mock- or P2X7-transfected HEK
293 cells was performed as previously described (Gadeock et al., 2012). HEK
293 cells were washed three times in NaCl medium (145 mM NaCl, 5 mM KCl,
10 mM HEPES, 0.1% bovine serum albumin and 5 mM glucose pH 7.4) and
harvested by mechanical scraping. Cells were pre-incubated at 37°C for 5 min,
or for P2X7 antagonist studies in the absence or presence of antagonists (as
indicated) at 37°C for 15 min. Cells were then incubated in 25 µM ethidium+ (or
1 µM YO-PRO-12+ or 25 µM propidium2+ as stated) and in the absence or
presence of ATP for 5 min (unless otherwise stated). The incubations were
stopped by the addition of 1 mL of ice-cold MgCl2 solution (NaCl medium
containing 20 mM MgCl2) and centrifugation (300 x g for 5 min). Cells were
washed once in NaCl medium (300 x g for 5 min) and data was acquired by
flow cytometry, using a LSR II flow cytometer and FACSDiva software (BD
Bioscience, San Diego, CA). A total of 1 x 104 events were collected and the
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mean fluorescence intensity (MFI) was measured using an emission window of
575/26 for ethidium+ (or 515/20 for YO-PRO-12+ or 695/40 for propidium2+).
FlowJo 8.7.1 software (Tree Star Inc., Ashland, CA) was used to analyse
collected data.

3.1.7 Presentation of data and statistical analysis
Results are expressed as mean ± standard deviation (SD). All graphs were
prepared using GraphPad Prism 5 (GraphPad Software, Inc. La Jolla, CA).
Differences between each treatment were compared using either the unpaired
Student’s t-test for single comparisons to control samples or ANOVA for
multiple comparisons (with Tukey’s post hoc test) using GraphPad Prism 5
software with P < 0.05 considered significant.
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3.2 Results
3.2.1 Canine P2X7 cDNA contains two single nucleotide polymorphisms
Canine P2X7 has previously been cloned from a Beagle (Roman et al., 2009)
with

near

identical

amino

acid

sequence

(except

a

Phe103Leu

SNP;

rs23314713) compared to the NCBI reference sequence for P2X7 deduced from
a Boxer (Accession no: NP_001106927). Our group recently cloned the canine
P2X7 receptor from an English Springer Spaniel and inserted into a pcP2X7Ac-N1 plasmid (Jalilian, 2011). This construct was sequenced and the amino
acid sequence was compared to the National Centre for Biotechnology
Information (NCBI) canine P2X7 reference sequence. Two non-synonymous
(missense) single nucleotide polymorphisms (SNPs) were identified in the P2X7
construct (Fig. 3.1). The first SNP changed the leucine at amino acid position
440 (TTG

TTT) to phenylalanine (Leu440Phe; Fig. 3.1). The second SNP

changed the proline at amino acid position 452 (CCT

TCT) to serine

(Pro452Ser; Fig. 3.1). A synonymous SNP was found at amino acid position 415
(CTG

TTG).
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Figure 3.1: ClustalW alignment of the amino acid sequence from the NCBI canine
P2X7 reference sequence and the canine P2X7 construct. The canine P2X7 cDNA
construct was sequenced by PCR and the sequence was compared to the NCBI
reference sequence (Accession no: NP_001106927). Two non-synonymous SNPs were
identified at positions Leu440Phe and Pro452Ser as indicated.

3.2.2 Canine P2X7-transfected HEK 293 cells express P2X7 protein
HEK 293 cells were transfected without (mock) or with canine P2X7 cDNA as
previously described within our laboratory (Peranec, 2011). To determine if the
mock-

or

canine

P2X7-transfected

cells

contained

P2X7

protein,
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immunoblotting of whole cell lysates was performed using anti-P2X7 Abs.
Human RPMI 8226 multiple myeloma cells, which contain P2X7 protein
(Farrell et al., 2010), were used as a positive control. Using anti-P2X7
polyclonal Abs (targeting either intracellular or extracellular epitope) a major
band was detected at 68-72 kDa, which corresponds to the molecular weight of
non-glycosylated P2X7, in RPMI 8226 cells and canine P2X7-transfected HEK
293 cells but not mock-transfected HEK 293 cells (Fig. 3.2). A second major
band at 155-160 kDa, possibly a P2X7 dimer, was also present in RPMI 8226
cells and canine P2X7-transfected HEK 293 cells, but not in mock-transfected
HEK 293 cells (Fig. 3.2). A faint 75 kDa band was detected in mock-transfected
HEK 293 cells by the anti-P2X7 polyclonal Ab targeting the intracellular
epitope but not the anti-P2X7 polyclonal Ab targeting the extracellular epitope
(Fig. 3.2).

3.2.3 ATP induces ethidium+ uptake into canine P2X7-transfected but not
mock-transfected HEK 293 cells
To determine if P2X7-transfected HEK 293 cells express functional canine
P2X7, mock- or canine P2X7-transfected HEK 293 cells were incubated with
ethidium+ in the absence or presence of 1 mM ATP for 5 min and the amount of
ethidium+ uptake measured by flow cytometry. As expected, ATP did not induce
ethidium+ uptake into mock-transfected HEK 293 cells compared to mocktransfected cells incubated without ATP (Fig. 3.3). In contrast, ATP significantly
induced ethidium+ uptake into P2X7-transfected HEK 293 cells compared to
P2X7-transfected cells incubated without ATP (Fig. 3.3). Ethidium+ uptake in
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the absence of ATP (basal) was similar between the two treated cell lines (Fig.
3.3).
Intracellular
epitope
RPMI P2X7 Mock MW

Extracellular
epitope
RPMI P2X7 Mock
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Figure 3.2: Canine P2X7-transfected HEK 293 cells express P2X7 protein. Cell
lysates of RPMI 8226 cells (positive control), and mock- or P2X7-transfected HEK 293
cells, as well as molecular weight (MW) markers, were separated by electrophoresis
and proteins were transferred to a nitrocellulose membrane. Membranes were
incubated with rabbit anti-P2X7 pAb (intracellular or extracellular epitope) followed by
HRP-conjugated goat-anti-rabbit IgG Ab or streptactin-HRP conjugate and visualised
using chemiluminescent substrate and hyperfilm.

3.2.4 ATP induces ethidium+ uptake into canine P2X7-transfected HEK
293 cells in time-dependent manner
To ensure the ATP incubation time of 5 min is suitable for further
pharmacological characterisation of the recombinant P2X7 receptor, canine
P2X7-transfected HEK 293 cells were incubated with ethidium+ in the absence
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or presence of ATP for 2, 4 or 6 min. Ethidium+ uptake in the absence of ATP
(basal) did not change with incubation time (Fig. 3.4). In contrast, ethidium+
uptake in the presence of ATP increased in a time-dependent manner and
remained linear over 6 min (Fig.3.4). Therefore, 5 min ATP incubations were
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Figure 3.3: ATP induces ethidium+ uptake into canine P2X7-transfected but not
mock-transfected HEK 293 cells. (A, B) Mock- or P2X7-transfected HEK293 cells
were incubated with 25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP
at 37°C for 5 min. The incubations were stopped by the addition of ice-cold MgCl2
solution and centrifugation. The MFI of ethidium+ uptake was measured by flow
cytometry. (A) (left panels) Viable cells were gated by forward and side scatter and
(right panels) histograms show relative ethidium+ uptake into basal (shaded) and ATPtreated (solid line) cells. (B) Results are expressed as the mean ± SD (n = 3). *** P <
0.001 compared to corresponding cells incubated without ATP.
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Figure 3.4: ATP induces ethidium+ uptake into canine P2X7-transfected HEK 293
cells in a time-dependent manner. P2X7-transfected HEK 293 cells were incubated
with 25 µM ethidium+ in the absence (Basal) or presence of 1 mM ATP at 37°C for 2, 4
or 6 min. The incubations were stopped by the addition of ice-cold MgCl2 solution and
centrifugation, and the MFI measured by flow cytometry. Results are expressed as the
mean ± SD (n = 3). *** P < 0.001 compared to corresponding cells incubated without
ATP.

3.2.5 P2X7

agonists

induce

ethidium+

uptake

into

canine

P2X7-

transfected HEK 293 cells
To characterise the pharmacology of the recombinant canine P2X7 receptor,
canine P2X7-transfected HEK 293 cells were first incubated with ethidium+ in
the absence or presence of various concentrations of ATP, BzATP and ATPγS for
5 min. All three compounds induced ethidium+ uptake into cells in a
concentration-dependent

manner

(Fig.

3.5).

The

half-maximal

effective

concentration (EC50) values for ATP, BzATP and ATPγS were 253 µM, 13 µM
and 438 µM respectively. Thus, similar to human and rodent P2X7 (Donnelly-
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Roberts et al., 2009), the relative agonist potency against canine P2X7 was
revealed to be BzATP > ATP > ATPγS.
Canine P2X7-transfected HEK 293 cells were then incubated with ethidium+ in
the absence or presence of ATP, P2Y agonists ADP or UTP, or P2X agonist α,βmeATP (all 1 mM) for 5 min. Again, ATP significantly induced ethidium+ uptake
into cells compared to cells incubated without ATP (basal) (Fig. 3.6). In
contrast, ADP, UTP and α,β-meATP failed to induce ethidium+ uptake into cells

Relative Ethidium+ Uptake
(Percent of Maximum)

compared to cells incubated in the absence of these agonists (basal) (Fig. 3.6).
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Figure 3.5: P2X7 agonists induce ethidium+ uptake into canine P2X7-transfected
HEK 293 cells in a concentration-dependent manner. P2X7-transfected HEK 293
cells were incubated with 25 µM ethidium+ in the absence or presence of varying
concentrations of BzATP, ATP or ATPγS (as indicated) at 37°C for 5 min. The
incubations

were

stopped

by

the

addition

of

ice-cold

MgCl2

solution

and

centrifugation. The MFI of ethidium+ uptake was measured by flow cytometry.
Ethidium+ uptake was calculated as the difference between agonist and the
corresponding basal treatments, and the results expressed as percent maximal
ethidium+ uptake compared to 50 µM BzATP-induced ethidium+ uptake. Results are
expressed as the mean ± SD (n = 3).
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Figure 3.6: ATP but not ADP, UTP or αβ-meATP induces ethidium+ uptake into
canine P2X7-transfected HEK 293 cells. P2X7-transfected HEK 293 cells were
incubated with 25 µM ethidium+ in the absence (basal) or presence of ATP, ADP, UTP
or α,β-meATP (all 1 mM) at 37°C for 5 min. The incubations were stopped by the
addition of ice-cold MgCl2 solution and centrifugation, and the MFI of ethidium+
uptake was measured by flow cytometry. Results are expressed as the mean ± SD (n =
3). *** P < 0.001 compared to corresponding cells incubated without agonist (basal).

3.2.6 P2X7 antagonists impair ATP-induced ethidium+ uptake into canine
P2X7-transfected HEK 293 cells
A438079 (Nelson et al., 2006), AZ10606120 (Michel et al., 2008), AZ11645373
(Stokes et al., 2006), Brilliant Blue G (BBG) (Jiang et al., 2000) and KN-62
(Gargett and Wiley, 1997) are all well-established P2X7 antagonists (Syed and
Kennedy, 2012). However, the ability of these antagonists to inhibit P2X7
varies between species (Donnelly-Roberts et al., 2009). Therefore, to determine
if these antagonists inhibit canine P2X7, canine P2X7-transfected HEK 293
cells were pre-incubated in the absence or presence of varying concentrations
of A438079, AZ10606120, AZ11645373, BBG and KN-62, and then incubated
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with ethidium+ in the absence or presence of 250 µM (EC50) ATP. All five
antagonists inhibited ATP-induced ethidium+ uptake into P2X7-transfected
HEK 293 cells in a concentration-dependent manner (Fig. 3.7), with IC50 values
of 190 nM, 11 nM, 7 nM, 1110 nM and 19 nM respectively. All five antagonists
completely inhibited ethidium+ uptake into P2X7-transfected HEK 293 cells at
concentrations of 0.1 µM (AZ11645373 and AZ10606120), 1 µM (KN-62) or 10
µM (A-438079 and BBG). Thus, the relative antagonist potency against canine
P2X7 was revealed to be AZ11645373 = AZ10606120 > KN-62 > A438079 >>

Relative Ethidium+ Uptake
(Percent of Maximum)
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Figure 3.7: P2X7 antagonists inhibit ATP-induced ethidium+ uptake into canine
P2X7-transfected HEK 293 cells in a concentration-dependent manner. P2X7transfected HEK 293 cells were pre-incubated in the absence or presence of various
concentrations of A438079, AZ10606120, AZ11645373, BBG or KN-62 at 37°C for 15
min. Cells were then incubated with 25 µM ethidium+ in the absence or presence of
250 µM ATP at 37°C for 5 min. The incubations were stopped by the addition of icecold MgCl2 solution and centrifugation. The MFI of ethidium+ uptake was measured by
flow cytometry. Ethidium+ uptake was calculated as the difference between agonist
and the corresponding basal treatments, and the results are expressed as percent
maximal ethidium+ uptake compared to ethidium+ uptake in the absence of
antagonist. Results are expressed as the mean ± SD (n = 3).
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3.2.7 ATP induces ethidium+, YO-PRO-12+ and propidium2+ uptake into
canine P2X7-transfected HEK 293 cells
The P2X7 pore in other species is a non-selective cation channel (North, 2002).
Therefore, to determine if canine P2X7 activation mediated the uptake of
cations other than ethidium+, canine P2X7-transfected HEK 293 cells were
incubated with ethidium+ (314 Da), YO-PRO-12+ (375 Da) or propidium2+ (415
Da) in the absence or presence of ATP for 5 min. ATP induced significant

Relative Fluorescent Dye Uptake
(Mean Fluorescence Intensity)

uptake of all three cations compared to cells incubated without ATP (Fig. 3.8).
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Figure 3.8: ATP induces ethidium+, YO-PRO-12+ and propidium2+ uptake into
canine P2X7-transfected HEK 293 cells. P2X7-transfected HEK 293 cells were
incubated with 25 µM ethidium+, 1 µM YO-PRO12+ or 25 µM propidium2+ in the
absence (basal) or presence of 1 mM ATP at 37°C for 5 min. The incubations were
stopped by the addition of ice-cold MgCl2 solution and centrifugation, and the MFI
measured by flow cytometry. Results are expressed as the mean ± SD (n = 3). ** P <
0.01; *** P < 0.001 compared to corresponding cells incubated without ATP (basal).
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3.3 Discussion
Canine P2X7 was first cloned and pharmacologically characterised by Roman
et al. (2009) from a Beagle. The current study characterised recombinant P2X7
cloned from an English Springer Spaniel due to previous data obtained on the
native P2X7 receptor from the same breed within our group (Sluyter et al.,
2007, Stevenson et al., 2009). The canine P2X7 construct was first sequenced
and compared to the corresponding NCBI reference sequence deduced from a
Boxer (Accession no: NP_001106927). The P2X7 cDNA sequence was near
identical to the reference sequence, containing 595 amino acids (Fig. 3.1).
Compared to human P2X7, the cloned canine P2X7 receptor in this study and
that of Roman et al. (2009), as well as the reference sequence contained an
additional threonine residue at position 284, while the valine residue at
position 538 was lacking. Three SNPs were identified in the P2X7 receptor
cloned from an English Springer Spaniel, of which two were non-synonymous
(missense) SNPs. A change in the amino acid residue at position 452 from
proline to serine (Pro452Ser) was identified. This SNP has been reported
previously online (www.ensembl.org; rs22315462). It is not known, however, if
Pro452Ser alters P2X7 function. Next, a change in the amino acid residue at
position 440 from leucine to phenylalanine (Leu440Phe) was identified. This
SNP has not been previously reported and it remains unknown if Leu440Phe
alters P2X7 function. Lastly, a synonymous SNP was identified in amino acid
position 415, changing the nucleobase from C→T; this SNP has also not been
previously reported.
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The size of the protein encoded by the canine P2X7 construct was examined by
via immunoblotting. A major band at 68-72 kDa was detected in human RPMI
8226 cells (positive control) and canine P2X7-transfected HEK 293 cells, but
not in mock-transfected HEK 293 cells (Fig. 3.2). This corresponds to the
predicted size of glycosylated P2X7. A second major band at 155-160 kDa,
which corresponds to the predicted size of P2X7 dimers, was detected in RPMI
8226 cells and canine P2X7-transfected HEK 293 cells, but not in mocktransfected HEK 293 cells (Fig. 3.2). A faint band at 75 kDa was detected in
mock-transfected HEK 293 cells using the anti-P2X7 polyclonal Ab targeting
the intracellular epitope (Fig. 3.2). This may indicate that HEK 293 cells
express small amounts of P2X7. However, the band was not detected in mocktransfected HEK 293 cells using the anti-P2X7 polyclonal Ab targeting the
extracellular epitope, suggesting that the band detected by the Ab against the
intracellular epitope is caused by non-specific binding. It should be noted
however, that despite loading equal amounts of protein onto the gel, this was
not confirmed by the use of a housekeeping protein such as actin. Thus, the
possibility remains that the absence of P2X7 in mock-transfected cells is due to
differences in loading. Moreover, it should be noted that the current study did
not employ an empty vector for mock-transfected cells, but rather cells which
were treated with Lipofectamine 2000 only. Thus, the possibility remains that
transfection of cDNA into HEK 293 cells causes upregulation of endogenous
P2X7. However previous studies by our group (Wiley et al., 2003, Stokes et al.,
2011) and others (Wilson et al., 2002) have repeatedly shown that transfection
of HEK 293 cells with empty vector cDNA does not induce expression of
functional P2X7 receptors.
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The agonist profile deduced from P2X7 cloned from an English Springer
Spaniel was similar to that of native P2X7 in red blood cells from the same
breed (Sluyter et al., 2007, Stevenson et al., 2009). ATP induced ethidium+
uptake into canine P2X7-transfected HEK 293 cells compared to cells
incubated in the absence of ATP in a time-dependent manner (Fig. 3.4). ATP,
BzATP and ATPγS induced ethidium+ uptake into P2X7-transfected cells in a
concentration-dependent manner with a rank order of potency of BzATP > ATP
> ATPγS (Fig. 3.5). The EC50 value obtained for BzATP (13 µM) was similar to
that of native P2X7 (Sluyter et al., 2007, Stevenson et al., 2009). Moreover,
BzATP was a complete agonist of recombinant canine P2X7 in the current
study, as previously found for native P2X7 (Sluyter et al., 2007, Stevenson et
al., 2009). The EC50 value obtained for ATP (235 µM) at the recombinant canine
P2X7 receptor was also comparable to that of native P2X7 (Sluyter et al., 2007,
Stevenson et al., 2009). ATPγS was the least potent agonist of the recombinant
canine P2X7 receptor with an EC50 value of 438 µM. This result is consistent
with the study by Sluyter et al. (2007) where ATPγS was found to be a partial
agonist of native canine P2X7 receptors. The potencies of BzATP, ATP and
ATPγS for P2X7 cloned from an English Springer Spaniel and to that for native
canine P2X7 from the same breed (Sluyter et al., 2007) is comparable to that
obtained for recombinant human P2X7 (Donnelly-Roberts et al., 2009). ADP,
UTP and α,β-meATP failed to induce ethidium+ uptake into P2X7-transfected
HEK 293 cells (Fig. 3.6). These agonists of other P2 receptors have previously
shown to be ineffective at human, rodent and canine P2X7 receptors (DonnellyRoberts et al., 2009, Sluyter et al., 2007).
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A

previous

study

by

Roman

et

al.

(2009),

which

pharmacologically

characterised recombinant P2X7 cloned from a boxer, showed comparable EC50
values for BzATP (21 µM) and ATP (1 mM) compared to P2X7 cloned from an
English Springer Spaniel. The study by Roman et al. (2009), however,
demonstrated that BzATP is a partial agonist of canine P2X7 compared to ATP,
contrasting the current study. Of note, the current study incubated P2X7transfected HEK 293 cells with agonists for 5 min, whereas the study by
Roman et al. (2009) used a 16 min incubation time. In addition, the current
study cloned P2X7 from a different breed compared to the study by Roman et
al. (2009). Thus, this may account for some of the differences between the
action of BzATP and ATP. It should be noted however, that BzATP is also
considered a partial agonist of the Guinea pig P2X7 receptor (Fonfria et al.,
2008). In contrast, BzATP is a complete agonist of human P2X7 compared to
ATP (Donnelly-Roberts et al., 2009). Therefore, further studies are required to
determine whether or not BzATP is a true complete agonist of canine P2X7.
Each of the five P2X7 antagonists studied completely impaired ATP-induced
ethidium+ uptake in canine P2X7-transfected HEK 293 cells with a rank order
of potency of AZ11645373 = AZ10606120 > KN-62 > A438079 > BBG (Fig. 3.7).
The IC50 values obtained from AZ11645373 (7 nM), AZ10606120 (11 nM) and
KN-62 (19 nM) were comparable to that previously obtained for recombinant
canine and human P2X7 (Donnelly-Roberts et al., 2009, Roman et al., 2009).
Moreover, the IC50 value for KN-62 against recombinant canine P2X7 is similar
to that of native P2X7 in red blood cells from English Springer Spaniels
(Stevenson et al., 2009). The IC50 value of A438079 (190 nM) for the canine
P2X7 receptor has not been determined previously, however our group recently
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demonstrated that A438079 impairs ATP-induced organic dye uptake into
MDCK cells and canine monocytes (Jalilian, 2011). Compared to recombinant
human P2X7 (Donnelly-Roberts et al., 2009), A438079 was five-fold more
potent at impairing the P2X7 receptor cloned from an English Springer Spaniel.
However, the study by Donnelly-Roberts et al. (2009) used a different assay
medium (PBS without Mg2+ or Ca2+), agonist (BzATP) and organic dye (YO-PRO12+) compared to the current study. Thus, the assay variations may account for
the potency differences of A438079 at human and canine P2X7 receptors. BBG
was the least potent antagonist of the P2X7 receptor cloned from an English
Springer Spaniel. The IC50 value (1110 nM) was 23-fold higher compared to the
IC50 value for BBG blockade at the canine P2X7 receptor cloned by Roman et
al. (2009). Of note, the study by Roman et al. (2009) cloned the P2X7 receptor
from a different breed (Beagle), and thus may account for the higher potency of
BBG at this receptor compared to that of the current study. Moreover, the IC50
value of BBG at the P2X7 receptor cloned from an English Springer Spaniel
was comparable to that previously obtained for recombinant human P2X7
(Donnelly-Roberts et al., 2009). Despite some differences in IC50 values at some
P2X7 antagonists, the current study confirms that canine P2X7 can be blocked
by numerous P2X7 antagonists as previously observed by our group
(Stevenson et al., 2009, Sluyter et al., 2007) and others (Roman et al., 2009).
Thus, this suggests P2X7 drugs developed to block P2X7 in humans may also
be of therapeutic value in dogs.
The P2X7 pore is known to be permeable for organic cations up to 900 Da
following prolonged exposure to ATP (Surprenant et al., 1996a). The current
study demonstrated that ATP induced ethidium+ (314 Da), YO-PRO-12+ (375
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Da) and propidium2+ (415 Da) uptake into P2X7-transfected HEK 293 cells (Fig.
3.8). The canine P2X7 receptor has previously been shown to be permeable to
choline+ (104 Da) (Sluyter et al., 2007, Stevenson et al., 2009), ethidium+
(Roman et al., 2009, Stevenson et al., 2009) and YO-PRO-12+ (Jalilian, 2011,
Peranec, 2011). ATP-induced propidium2+ uptake however has not been
previously demonstrated for the canine P2X7 receptor. Of note, P2X7 activation
also mediates propidium2+ uptake into other cell types, including HEK 293
cells expressing recombinant human P2X7 and rat bone nodule cells (Milius et
al., 2007, Panupinthu et al., 2008). Thus propidium2+ uptake is not unique to
canine P2X7, and this receptor allows uptake of cations at least 415 Da in size.
In conclusion, this study sequenced and pharmacologically characterised
canine

recombinant

P2X7

cloned

from

an

English

Springer

Spaniel.

Sequencing identified two non-synonymous SNPs: Leu440Phe and Pro452Ser.
Moreover, the cloned receptor could form functional P2X7 receptors in
transfected HEK 293 cells with characteristics similar to native canine and
recombinant human P2X7.
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Chapter 4: Relative P2X7 function differs amongst dogs:
possible role for polymorphisms in the P2RX7 gene

4.1 Materials and Methods
4.1.1 Materials
Allophycocyanin

(APC)-conjugated

anti-human/canine

CD14

monoclonal

antibody (mAb) (clone M5E2) was from BioLegend (San Diego, CA). SPHERO
Rainbow Fluorescent Particles were from Spherotech (Lake Forest, IL). Mango
Taq DNA polymerase, 5X MangoTaq Colorless Reaction Buffer, MgCl2 and dNTP
master mix were from Bioline (Alexandria, Australia). Primers for genomic DNA
PCRs and sequencing were from Geneworks (Hindmarsh, Australia). ExoSAP-IT
PCR Clean-up Kit was from GE Healthcare (Buckinghamshire, United
Kingdom). The remainder of materials are described in Chapter 2 and 3.

4.1.2 Cell lines
Madin-Darby canine kidney (MDCK) epithelial cells were purchased from the
European Collection of Cell Cultures (Porton Down, UK). Cells were cultured in
DMEM/F12 medium supplemented with 10% foetal calf serum (FCS), 2 mM
GlutaMAX, 100 units/mL penicillin and 10 µg/mL streptomycin (complete
culture medium). Cells were incubated at 37°C/5% CO2 and were passaged
two times per week by limited trypsinisation, as required.
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4.1.3 Collection of blood
Peripheral blood from 30 mixed and pure breed dogs was collected into
vacutainer tubes containing lithium heparin (Greiner Bio-One, Frickenhausen,
Germany), from either Albion Park Veterinary Hospital (Albion Park, Australia)
or Oak Flats Veterinary Clinic (Oak Flats, Australia). Written consent was
obtained from informed owners with approval by the University of Wollongong
animal ethics committee. Peripheral blood from five human volunteers was
collected as above, with written consent and approval by the University of
Wollongong human ethics committee.

4.1.4 Isolation of peripheral blood mononuclear cells
Blood from 22 dogs was centrifuged (450 x g for 15 min; with brake off) and the
buffy coat was collected. Buffy coats were diluted with Dulbecco’s phosphatebuffered saline (D-PBS), underlaid with Ficoll-Paque PLUS and centrifuged (560
x g for 20 min; with brake off). The peripheral blood mononuclear cells (PBMCs)
were collected and washed twice with D-PBS (450 x g for 10 min followed by
300 x g for 5 min) and once in NaCl medium (145 mM NaCl, 5 mM KCl, 10 mM
HEPES, 0.1% bovine serum albumin (BSA) and 5 mM glucose pH 7.4) (300 x g
for 5 min). PBMCs were then suspended in NaCl medium at 2 x 106 cells/mL.

4.1.5 Detection of P2X7 function in peripheral blood monocytes by flow
cytometry
An ATP-induced YO-PRO-12+ uptake assay to measure P2X7 function was
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performed as previously described (Peranec, 2011, Jalilian, 2011). PBMCs (in
duplicate) were pre-incubated at 37°C for 5 min, then with 1 µM YO-PRO-12+ in
the absence or presence of 1 mM ATP for 5 min at 37°C. Incubations were
stopped by adding an equal volume of ice-cold MgCl2 solution (NaCl medium
containing 20 mM MgCl2) and centrifugation (300 x g for 5 min). PBMCs were
washed once in NaCl medium (300 x g for 5 min) and incubated with the APCconjugated anti-CD14 mAb in the dark at room temperature for 15 min.
PBMCs were then washed once in NaCl medium (300 x g for 5 min) and the
data was acquired by flow cytometry, using a LSR II flow cytometer and
FACSDiva software (BD Bioscience, San Diego, CA). A total of 1 x 105 events
were collected using emission windows of 515/20 and 660/20 nm for YO-PRO12+ and APC, respectively. For each sample, the 515/20 nm voltage was
adjusted using SPHERO Rainbow Fluorescent Particles to a mean fluorescent
intensity of 10000. FlowJo 8.7.1 software (Tree Star Inc., Ashland, CA) was
used to analyse collected data. Relative P2X7 function was determined as the
difference in YO-PRO-12+ uptake into CD14+ cells in the presence and absence
of ATP, and is expressed as the mean of duplicate samples.

4.1.6 Amplification of the canine P2RX7 gene
Genomic DNA was isolated from peripheral blood from 30 dogs or MDCK cells
using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI)
according to the manufacturer’s instructions. The quality of the DNA was
assessed by electrophoresis, using a 1% agarose gel at 100 V for 60 min in Tris
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acetate-EDTA (TAE) buffer (20 mM acetic acid, 1 mM EDTA, 40 mM Tris, pH 8),
and staining with ethidium bromide.
Primers for exons 3, 9, 10 (forward), 11 (reverse), 12 and 13a of the canine
P2XR7 gene were obtained from Michelle Peranec (University of Wollongong,
Australia). The remaining exon sequences of P2RX7 from Canis familiaris were
retrieved from the Ensembl database (http://www.ensembl.org, accession
number NP_001106927), together with the flanking intronic regions. These
sequences were submitted into the online primer design program Primer3
(http://frodo.wi.mit.edu/ primer3/). Candidate primers were then analyzed for
their ability to form hairpins, self- and hetero-dimers using the online
OligoAnalyzer

3.1

program

(http://www.idtdna.com/analyzer/Applications

/OligoAnalyzer/). The resulting primer sequences are shown in Table 4.1.

Table 4.1 Primer pairs used to amplify and sequence canine P2RX7 gene exons.
Exon

Forward Primer 5’-3’

Reverse Primer 5’-3’

Product
Size (Bp)

Annealing
Temperature

1
2

AGGATTGAACCCTCCTCGTT
AAGTAGCCTGCCCAGAGTCA

TCAAGATGTGCACCAGAAGC
TTTTGAGCTGCTGGATCTGA

263
486

58.7 ºC
64.1 ºC

3

AGTCCAAGTTGCTCCCAGAC

GAGGACAGAAGAGGGAAAAGA

349

63.1 ºC

4

TCCTGTTGTAGCAGGTGCAG

GCTGAGAGCCAGAGGCTAAA

423

64.1 ºC

5

AAAAAGCCAACAGCATCCAC

CTCTTCCTCCCCTGCTCTTT

741

60.0 ºC

6

GGGCCTCAGGAAGAGAGAAG

CCCACAGAAACTGCATCAGA

346

64.5 ºC

7

CATGGAACCCAGCTACCAAC

GCACTGTGCCGGGATATACT

353

64.1 ºC

8

TTTAATCTGCGTTCCCCTCT

AAGCCTTTTGCATTCATCTTG

368

63.1 ºC

9

TGAAATACCAGCATGTTCACAC

GGACATTTCTTCCCCCTCTT

263

58.7 ºC

10

GCTGACAATTACATGGTAGAGCA

CTAAAGTGTAGGAAAGAGAA

170

62.2 ºC

11

CTCACTAACTCGCACTGAT

TGATTTTGGCCTTATTTTTGC

262

62.2 ºC

12

GAATAACACTTGCCTTTAGATATGTTC

TGGGTTACATGTACTTAATGTGTTAAA

300

60.0 ºC

13a

GAACCTTAGGGGTGGTCACT

CAAGCTCAGGTGCAAACAAA

600

64.1 ºC

13b

TTTCAGAGACCCTCAATGGAA

TCAACCCTGTGCCATCAGTA

515

58.6 ºC
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Each PCR reaction contained 1X Mango Taq Colourless Reaction Buffer, 3.5
mM MgCl2, 100 µM dNTP, 1 µM forward and reverse primer, 1 U Mango Taq
DNA Polymerase, 1 µL DNA template and sterile deionised H2O to a final
volume of 20 µL. The PCR was performed using a Mastercycler Pro S
thermocycler (Eppendorf, Germany) with an initial denaturation at 94 ºC for 1
min, followed by 35 cycles of denaturation at 94ºC for 30 sec, annealing at
58.6-64.5 ºC (Table 4.1) for 30 sec, and extension at 72ºC for 1 min. After the
cycling was completed, a final extension at 72ºC for 5 min was performed, and
the reactions returned to room temperature (30ºC for 1 min). PCR products
were separated via electrophoresis using a 1.5% agarose gel at 100 V for 1 hour
in TAE buffer and ethidium bromide staining.

4.1.7 Sequencing of exons 1-13 of the canine P2RX7 gene
PCR products were purified using 1 µL of diluted (1:4) ExoSAP-IT enzyme per
2.5 µL of PCR product, and the samples incubated using a Mastercycler Pro S
thermocycler at 37ºC for 15 min, and then 80ºC for 15 min. Sequencing
reactions were performed as described in section 2.1.6, using the primers
described in Table 4.1. Purification of ExoSAP-IT treated PCR products was
performed as described in section 2.1.6. Resulting sequences were compared to
the NCBI reference sequence (Accession no: NM_001113456.1) using Geneious
Pro Software (Biomatters, Auckland, New Zealand). Identified single nucleotide
polymorphisms (SNPs) were confirmed by repeating PCRs.
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4.1.8 Data presentation and statistical analysis
Data is expressed as mean ± SD (and ranges where indicated). All graphs were
prepared using GraphPad Prism 5 (GraphPad Software, Inc. La Jolla, CA).
Differences between each treatment were compared using either the unpaired
Student’s t-test for single comparisons to control samples or ANOVA for
multiple comparisons (with Tukey’s post hoc test) using GraphPad Prism 5
software with P < 0.05 considered significant.
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4.2 Results
4.2.1 Relative P2X7 function of monocytes varies between and within dog
breeds
To determine whether P2X7 function varies between and within breeds the
relative P2X7 function of canine monocytes from 43 dogs has been measured
previously within our laboratory (Jalilian, 2011, Peranec, 2011). Using the
same flow cytometric assay, ATP-induced YO-PRO-12+ uptake into canine
PBMCs was assessed in a further 22 dogs. The gating strategy used to study
YO-PRO-12+ uptake into CD14+ cells (monocytes) from two Siberian Huskies
with either high or low P2X7 function is shown in Figure 4.1. Figure 4.2
illustrates the relative P2X7 function in monocytes from all 65 dogs studied.
ATP induced YO-PRO-12+ uptake into monocytes from all dogs examined with
an average MFI of 154 ± 86 (range 21-466) and an average coefficient of
variation (CV) of 0.20 ± 0.22 (range 0.01-1.41). Relative P2X7 function varied
between dog breeds. The highest P2X7 function was observed in monocytes
from a Siberian Husky (MFI of 466), which was 22-fold greater than the lowest
value obtained from a Labrador (MFI of 21). Relative P2X7 function varied
among cross breed dogs, with approximately 13-fold difference between the
highest and lowest relative P2X7 function. The relative P2X7 function also
varied within some dog breeds. Amongst the pure breed dogs, the highest
variation in relative P2X7 function occurred in Siberian Huskies and
Labradors, with an 18- and 13-fold difference between the respective highest
and lowest values. Furthermore, the relative P2X7 function in Miniature
Dachshunds differed six-fold between the respective highest and lowest values.
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Differences in relative P2X7 function were also found between five Staffordshire
Bull Terriers, with a four-fold difference between the highest and lowest P2X7
function. In contrast, some dog breeds showed less variation in monocyte P2X7
function, such as the American Staffordshire Terrier (MFI of 77 and 85), Border
Collie (MFI of 149 and 191), Bull Terrier (MFI of 152 and 193), Golden Retriever
(MFI of 153, 159 and 188) and Miniature Fox Terrier (MFI of 80 and 123).

Figure 4.1: Gating strategy used for determining the relative canine monocyte
P2X7 function. Canine PBMCs from two Siberian Huskies were isolated using FicollPaque density centrifugation and suspended in NaCl medium containing 1 µM YOPRO-12+. PBMCs were then incubated in the absence or presence of 1 mM ATP at 37°C
for 5 min. Incubations were stopped by adding ice-cold MgCl2 solution and
centrifugation. Monocytes were incubated with APC-conjugated anti-CD14 mAb and
analysed by flow cytometry. (Left panels) PBMCs were gated by forward and side
scatter. (Centre panels) Monocytes were gated by relative CD14 expression. (Right
panels) Histograms showing basal (shaded) or ATP-induced (solid line) YO-PRO-12+
uptake into monocytes from two Siberian Huskies with low (top) or high (bottom) P2X7
function.
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Figure 4.2: Relative P2X7 function of monocytes varies between and within dog
breeds. Canine PBMCs from various dog breeds were isolated using Ficoll-Paque
density centrifugation and suspended in NaCl medium containing 1 µM YO-PRO-12+.
PBMCs were then incubated in the absence or presence of 1 mM ATP at 37°C for 5
min. Incubations were stopped by adding ice-cold MgCl2 solution and centrifugation.
Monocytes were incubated with APC-conjugated anti-CD14 mAb and analysed by flow
cytometry. Relative P2X7 function was determined by the difference in the YO-PRO-12+
uptake in the presence or absence of ATP. Results are expressed as the mean of
duplicate samples for each dog (n = 65). Broken line represents mean of all samples;
solid lines represent mean for each group.

4.2.2 Variation in dog P2X7 function may be due to experimental factors
To determine if sex or age differences are responsible for the variation in
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relative P2X7 function between dogs, the function data obtained in Figure 4.2
were grouped according to sex or age. Female dogs showed significantly lower
relative P2X7 function compared to male dogs (Fig. 4.3A). However, it should be
noted that this difference was largely attributed to four male dogs with
relatively high P2X7 function. In contrast, the relative P2X7 function did not
significantly alter between groups of animals separated by age (Fig. 4.3B).
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Figure 4.3: Relative P2X7 function varies with sex but not with age. Dogs were
grouped according to (A) sex or (B) age and compared to the relative monocyte P2X7
function (obtained from Fig. 4.2) compared. Solid line represent mean for each group.
* P < 0.05 compared to male dogs.
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Due to practical difficulties (including ethical restrictions) it was not possible to
obtain more than one sample from the same dog. Thus, it is also possible that
the variation in relative P2X7 function is due to interassay variation. Therefore,
ATP-induced YO-PRO-12+ uptake into human monocytes from five individuals
was assessed on four separate occasions over 72-81 days. ATP induced YOPRO-12+ uptake into monocytes from all subjects investigated with an average
MFI of 554 ± 403 (range 104-1415) (Fig 4.4). However, similar to dogs, the
relative P2X7 function varied between human subjects, with a 14-fold
difference between the highest value observed in subject 4 on day 0 (MFI of
1415) and the lowest value observed in subject 3 on day 75 (MFI of 104).
Subject 5 showed the greatest variation with time, with a five-fold difference
between the highest and lowest relative P2X7 function. Subjects 2 and 3
showed a three-fold difference in relative P2X7 function between the highest
and lowest values. Subjects 1 and 4 both showed a two-fold difference in
relative P2X7 function between the highest and lowest values. The interassay
variations from each individual subject are shown in Table 4.2.

4.2.3 Determination of relative quality and quantity of canine genomic
DNA
Genomic DNA was isolated from 120 dogs during the course of two previous
studies (Jalilian, 2011, Peranec, 2011) and the current study. To determine the
relative quality and quantity of the DNA, samples were separated by agarose
gel electrophoresis and stained with ethidium bromide. All samples contained
high molecular weight DNA, which indicates intact genomic DNA (Fig. 4.5; data
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not shown). Smeared bands were found in most samples, including the
examples from a Jack Russel Terrier, Staffordshire Bull Terrier and Sharpei,
indicating relatively high concentrations of DNA. Less smeared bands such as
examples from a Maltese cross Poodle and Maltese cross, indicate lower relative
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Figure 4.4: Relative P2X7 function varies between monocytes from human
subjects and within the same subject over time. PBMCs were isolated from five
human subjects, approximately every 3-4 weeks over a period of 72-81 days (on four
separate occasions as indicated), using Ficoll-Paque density centrifugation and
suspended in NaCl medium containing 1 µM YO-PRO-12+. PBMCs were then incubated
in the absence or presence of 1 mM ATP at 37°C for 5 min. Incubations were stopped
by adding ice-cold MgCl2 solution and centrifugation. Monocytes were incubated with
APC-conjugated anti-CD14 mAb, and analysed by flow cytometry. Relative P2X7
function was determined by the difference in the YO-PRO-12+ uptake in the presence
or absence of ATP. Results are expressed as the mean of duplicate samples for each
individual (n = 5).
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Table 4.2: Relative P2X7 function from human monocytes: interassay variations.
The average and range mean fluorescent intensity (MFI) of ATP-induced YO-PRO-12+
uptake into monocytes from each subject was obtained from Figure 4.4. CV represents
coefficient of variation; SD represents standard deviation.

ATP-induced YO-PRO-12+ uptake (MFI)
Subject

Average

SD

Range

CV

1

874

248

508-1048

0.28

2

239

98

150-378

0.41

3

178

111

104-342

0.62

4

1001

330

660-1415

0.33

5

479

322

216-994

0.67

Figure 4.5: Relative quality and quantity of canine genomic DNA. Genomic DNA
was isolated from dog peripheral blood and separated using a 1% agarose gel
electrophoresis and stained using ethidium bromide. Results are representative of 120
samples. X represents cross breed; H2O represents lane loaded with H2O and loading
buffer only; MW represents base pair (Bp) markers.

4.2.4 Amplification and sequencing of the canine P2RX7 gene
Variation in relative P2X7 function between humans is largely attributed to
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SNPs in the human P2RX7 gene (Sluyter and Stokes, 2011). To determine if the
variation in relative P2X7 function between dogs is caused by SNPs,
sequencing of the P2RX7 gene was carried out in 11 dogs with the highest
monocyte P2X7 function, 8 dogs with the lowest monocyte P2X7 function, as
well as MDCK cells which express low amounts of functional P2X7 (Jalilian,
2011). Each of the 13 exons were amplified by PCR, separated by agarose gel
electrophoresis and stained with ethidium bromide. Due to the short intron
between exons 10 and 11 these exons were amplified and sequenced as a
single product. The resulting products corresponded to the predicted size of
each exon (Fig. 4.6). The amplified DNA was then purified with ExoSAP-IT
enzyme, sequenced and compared to the NCBI reference sequence (accession
no: NM_001113456.1). A complete sequence was obtained for each exon,
except for exon 13, for which the sequence of the last 48 base pairs (or the final
16 amino acid residues of the C-terminus) could not be determined due to poor
signal to noise ratio. Four non-synonymous (missense) SNPs were identified in
the canine P2RX7 gene. Firstly, a T→C substitution in either heterozygous or
homozygous dosage was identified in exon 3 of eight dogs, which causes a
change in the amino acid residue at position 103 from phenylalanine to leucine
(Phe103Leu) (Fig 4.7). This SNP corresponded to the previously reported SNP,
rs23314713. Second, a C→T substitution in heterozygous dosage was
identified in exon 8 of one dog and in MDCK cells, which causes a change in
the amino acid residue at position 270 from arginine to cysteine (Arg270Cys)
(Fig. 4.8). Third, a G→A substitution in heterozygous dosage was identified in
exon 11 of one dog, causing a change in the amino acid residue at position 365
from arginine to glutamine (Arg365Gln) (Fig. 4.9). Fourth, a C→T substitution
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in either heterozygous or homozygous dosage was identified in exon 13 of 13
dogs and in MDCK cells, which causes a change in the amino acid residue at
position 452 from proline to serine (Pro452Ser) (Fig. 4.10). This SNP
corresponded to the previously reported SNP, rs22315462. Finally, a T→C
substitution was identified in either heterozygous or homozygous dosage in
exon 4 of 12 dogs and in MDCK cells, resulting in a synonymous SNP at
Asn131 (Fig. 4.11). This SNP corresponded to the previously reported SNP,
rs8660017. The four non-synonymous SNPs are summarised in Fig. 4.12 and
the genotypes of all 20 samples examined are summarised in Table 4.3.

MDCK P2RX7 exons
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Figure 4.6: PCR amplification of canine P2RX7 gene exons. Each exon was
amplified from genomic DNA (isolated from MDCK cells) by PCR, and the products
were separated using a 1.5% agarose gel electrophoresis and stained using ethidium
bromide. Similar results were observed for the 19 blood genomic DNA samples
examined.
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Figure 4.7: Partial sequence from canine P2RX7 exon 3 showing the Phe103Leu
SNP. Exon 3 from the canine P2RX7 gene was amplified and sequenced from MDCK
cells and 19 dogs with high or low monocyte P2X7 receptor function. A nonsynonymous SNP (T→C) in exon 3 resulting in a change from phenylalanine to leucine
(Phe103Leu) at amino acid position 103 was identified. Representative partial
sequences are shown from three animals with wild type (WT), homozygous
(Phe103Leu) and heterozygous (WT/Phe103Leu) genotype.

Figure 4.8: Partial sequence from canine P2RX7 exon 8 showing the Arg270Cys
SNP. Exon 8 from the canine P2RX7 gene was amplified and sequenced from MDCK
cells and 19 dogs with high or low monocyte P2X7 receptor function. A nonsynonymous SNP (C→T) in exon 8 resulting in a change from arginine to cysteine
(Arg270Cys) at amino acid position 270 was identified. Representative partial
sequences are shown from two animals with wild type (WT) and heterozygous
(WT/Arg270Cys) genotype.
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Figure 4.9: Partial sequence from canine P2RX7 exon 11 showing the Arg365Gln
SNP. Exon 11 from the canine P2RX7 gene was amplified and sequenced from MDCK
cells and 19 dogs with high or low monocyte P2X7 receptor function. A nonsynonymous SNP (G→A) in exon 11 resulting in a change from arginine to glutamine
(Arg365Gln) at amino acid position 365 was identified. Representative partial
sequences are shown from two animals with wild type (WT) and heterozygous
(WT/Arg365Gln) genotype.

Figure 4.10: Partial sequence from canine P2RX7 exon 13 showing the
Pro452Ser SNP. Exon 13 from the canine P2RX7 gene was amplified and sequenced
from MDCK cells and 19 dogs with high or low monocyte P2X7 receptor function. A
non-synonymous SNP (C→T) in exon 13 resulting in a change from proline to serine
(Pro452Ser) at amino acid position 452 was identified. Representative partial
sequences are shown from three animals with wild type (WT), homozygous (Pro452Ser)
and heterozygous (WT/Pro452Ser) genotype.
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Figure 4.11: Partial sequence from canine P2RX7 exon 4. Exon 4 from the canine
P2RX7 gene was amplified and sequenced from MDCK cells 19 dogs with high or low
monocyte P2X7 receptor function. A synonymous SNP (T→C) in exon 4, corresponding
to amino acid position 131, was identified. Representative partial sequences are shown
from two animals with wild type (WT) and homozygous (Asn131) genotype.

Figure 4.12: Summary of the non-synonymous SNPs identified in the canine
P2RX7 gene. Each exon of the canine P2RX7 gene from MDCK cells and 19 dogs was
amplified by PCR and sequenced. Four non-synonymous SNPs were identified:
Phe103Leu in exon 3; Arg270Cys in exon 8; Arg365Gln in exon 11; and Pro452Ser in
exon 13.

4.2.5 Complete sequencing of exon 3, 8, 11 and 13 of the canine P2RX7
gene
To determine if the identified SNPs in the canine P2XR7 gene alter monocyte
P2X7 function, 62 dogs for which we had both relative P2X7 function data and
genomic DNA, were screened for the Phe103Leu, Arg270Cys, Arg365Gln and
Pro452Ser SNPs. Genotypes were then compared to relative P2X7 function. The
Arg270Cys SNP had a prevalence of 2% and an allele frequency of 1% (61 wild
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type and one heterozygote). Although a statistical comparison could not be
performed due to identifying this SNP in only one dog, this SNP was observed
in a Cavalier King Charles Spaniel cross Cocker Spaniel with relatively low
monocyte P2X7 function (Fig. 4.13A), as well as MDCK cells (Table 4.3), which
express low amounts of functional P2X7 (Jalilian, 2011). The Arg365Gln SNP
had a prevalence of 6% and an allele frequency of 3% (58 wild type and four
heterozygotes). This SNP was exclusive to Labradors (pure or cross breed),
however not all Labradors contained the SNP. A small but non-significant
decrease in relative P2X7 function was observed in dogs heterozygous for the
SNP compared to wild type dogs (Fig. 4.13B). The Phe103Leu SNP had a
prevalence of 50% and an allele frequency of 25% (31 wild type, 13
heterozygotes and 18 homozygotes). A small but non-significant decrease in
relative P2X7 function was observed in dogs homozygous for the SNP compared
to wild type dogs (Fig. 4.13C). The Pro452Ser SNP had a prevalence of 61% and
an allele frequency of 40% (24 wild type, 27 heterozygotes and 11
homozygotes). Again a small but non-significant decrease in relative P2X7
function was observed in dogs homozygous for this SNP compared to wild type
dogs (Fig. 4.13D).
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Table 4.3: Summary of P2X7 genotypes from dogs with high and low monocyte
P2X7 function and MDCK cells. Genotypes from high and low monocyte P2X7
function dogs (obtained from Fig. 4.2) and MDCK cells. X represents cross breed; WT
represents wild type; 103 represents the Phe103Leu SNP; 131 represents the Asn131
SNP; 270 represents the Arg270Cys SNP; 365 represents the Arg365Gln SNP; 452
represents the Pro452Ser SNP.
Potential SNP : Gain of Function
Breed
Siberian Husky

P2X7
Function

Exon
1

2

3

4

5

6

7

8

9

10

11

12

13

466

WT WT

WT

WT

WT WT WT

WT

WT WT

WT

WT WT/452

Border Collie X Cattle Dog

395

WT WT

WT

131

WT WT WT

WT

WT WT

WT

WT

Sharpei

337

WT WT

WT

WT/131 WT WT WT

WT

WT WT

WT

WT WT/452

Red Cattle Dog

282

WT WT WT/103 WT/131 WT WT WT

WT

WT WT

WT

WT WT/452

Labrador

272

WT WT

WT

WT

WT WT WT

WT

WT WT

WT

WT WT/452

Jack Russell Terrier X

268

WT WT

103

WT

WT WT WT

WT

WT WT

WT

WT

Alaskan Malamute

263

WT WT

WT

131

WT WT WT

WT

WT WT

WT

WT WT/452

Shihtzu X Maltese

246

WT WT

WT

WT/131 WT WT WT

WT

WT WT

WT

WT

452

German Short Haired
Pointer

238

WT WT

WT

131

WT WT WT

WT

WT WT

WT

WT

452

Staffordshire Bull Terrier

238

WT WT

103

WT

WT WT WT

WT

WT WT

WT

WT

WT

Rhodesian Ridgeback

236

WT WT

WT

WT/131 WT WT WT

WT

WT WT

WT

WT WT/452

10

11

12

13

Potential SNP : Loss of Function
Breed

P2X7
Function

King Charles Cavalier X
Cocker Spaniel

44

Staffordshire Bull Terrier
X

WT

WT

Exon
1

2

3

4

5

6

WT WT

WT

131

WT WT WT WT/270 WT WT

WT

WT

452

39

WT WT

103

WT

WT WT WT

WT

WT WT

WT

WT

WT

Pug X Beagle

35

WT WT

103

131

WT WT WT

WT

WT WT

WT

WT

452

Jack Russel Terrier

32

WT WT

103

131

WT WT WT

WT

WT WT

WT

WT

WT

Golden Retriever X
Labrador

31

WT WT

103

131

WT WT WT

WT

WT WT WT/365 WT

WT

Miniature Dachshund

30

WT WT

103

131

WT WT WT

WT

WT WT

WT

WT

452

Siberian Husky

25

WT WT

WT

WT

WT WT WT

WT

WT WT

WT

WT WT/452

Labrador

21

WT WT

WT

WT/131 WT WT WT

WT

WT WT

WT

WT WT/452

10

11

12

WT/131 WT WT WT WT/270 WT WT

WT

WT WT/452

MDCK cells
Breed
Cocker Spaniel

7

8

9

Exon
1

2

WT WT

3
WT

4

5

6

7

8

9

13

100

A

B
500

Relative P2X7 Function
(ATP-induced YO-PRO-12+ Uptake)

Relative P2X7 Function
(ATP-induced YO-PRO-1 2+ Uptake)
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Figure 4.13: Canine P2RX7 SNPs and relative monocyte P2X7 function. Exons (A)
8, (B) 11, (C) 3, and (D) 13 from 62 dogs were sequenced as described (Fig. 4.7 and
4.10) and the genotype compared to the relative P2X7 function (obtained in Fig. 4.2).
WT represents wild type; 103 represents the Phe103Leu SNP; 131 represents the
Asn131 SNP; 270 represents the Arg270Cys SNP; 365 represents the Arg365Gln SNP;
452 represents the Pro452Ser SNP. Solid lines represent mean for each group.
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4.3 Discussion
The current study combined with previous investigations in our laboratory
(Jalilian, 2011, Peranec, 2011) demonstrate that ATP induced YO-PRO-12+
uptake into peripheral blood monocytes from 21 pure breeds and a range of
cross breeds (Fig. 4.2). Moreover, this data shows that the relative P2X7
function varied between breeds. Relative P2X7 function also varied within the
majority of pure breed dogs; however some breeds showed less variation, such
as American Staffordshire Terriers and Golden Retrievers. The reduced
variation in this latter group may reflect a sampling error as all dog breeds that
had four or more samples showed greater variation in P2X7 function.
The cause of the variation in P2X7 function between and within dog breeds
remains unknown. Sequencing of the canine P2RX7 gene identified four nonsynonymous SNPs. Three of these

SNPs, Arg365Gln, Phe103Leu and

Pro452Ser, did not correspond with a gain- or loss-of P2X7 function (Fig. 4.13).
The remaining SNP, Arg270Cys, was only observed in a single dog (Cavalier
King Charles Spaniel cross Cocker Spaniel) with low P2X7 function (Fig. 4.13)
as well as MDCK cells (Table 4.3), which express low amounts of functional
P2X7 (Jalilian, 2011). Thus, the Arg270Cys SNP may be a loss-of-function SNP
but does not account for the low P2X7 function in the other dogs.
The variation in P2X7 function between dogs may be partly explained by sex.
Female dogs showed significantly lower relative P2X7 function compared to
male dogs (Fig. 4.3A). However, this difference was largely attributed to four
male dogs with relatively high P2X7 function. It has been shown that the
oestrogen β-oestradiol impairs P2X7-evoked currents in P2X7-transfected cells
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(Cario-Toumaniantz et al., 1998), suggesting that the difference between dog
sexes may be attributed to the absence or presence of specific sex hormones. In
contrast to sex, age did not appear to affect relative P2X7 function between
dogs (Fig. 4.3B). A previous study has shown, however, that there is a
significant increase of P2X7 mRNA levels in mouse microglia from the animal
between the ages of 3 days old through to 21 days old, with steady levels after
21 days (Crain et al., 2009). A separate study shows a decline in P2X7 receptor
levels in mouse striatum from the age of 3 months through to 10 months (DíazHernández et al., 2009). The current study relied on information given by the
dog owners, thus the date of birth may be inaccurate in some instances.
Therefore, it cannot be ruled out that age affects relative P2X7 function from
canine monocytes.
The variation in P2X7 function between dogs may also be associated with
experimental errors. Due to ethical constraints in getting multiple blood
samples from the same dogs, the relative P2X7 function of human monocytes
was assessed at four separate occasions over a period of 72-81 days using the
same assay as for dog monocytes to assess the interassay variation. Similar to
dogs, the relative P2X7 function of human monocytes varied between subjects
(Fig. 4.4). The relative P2X7 function also varied with time for each subject. A
study using ATP-induced ethidium+ uptake measurements into human
monocytes and in PBMCs over 42 days showed similar variations with time,
with approximately a two-fold difference between the highest and lowest values
within all three subjects (Jursik et al., 2007). Thus, the variations in relative
P2X7 function of human monocytes may indicate natural fluctuations in P2X7
function over time. A second study however using BzATP-induced YO-PRO-12+
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uptake into human monocytes in whole blood over 3 months showed less than
a two-fold difference between the highest and lowest values within all eight
subjects (Korpi-Steiner et al., 2008). Thus it is possible that the variation in
P2X7 function in monocytes within canine PBMCs may be due to variation in
monocytes obtained following density centrifugation. Ideally, relative P2X7
function from monocytes of each dog should have been investigated at several
time-points. However, as noted above it was not possible to obtain more than
one sample from the same dog.
Other reasons for variation in P2X7 function between dogs may be attributed
to other influences. The medical history of the dogs were not recorded, thus
disease status, most notably diseases with an inflammatory component, may
have modulated P2X7 function. P2X7 expression, which correlates to P2X7
function (Gu et al., 2000) is known to be altered by inflammatory cytokines
(Gadeock et al.,

2010,

Humphreys

and

Dubyak,

1998).

Alternatively,

medications may have also altered relative P2X7 function. Our group has
shown that the gout drug probenecid can impair P2X7 function in human
leukemic cells (Gadeock et al., 2012). Finally, it is also possible that other P2X
receptors such as P2X4 and 5 contribute to the ATP-induced YO-PRO-12+
uptake in canine monocytes. P2X4 and 5 have previously been found in human
myeloid cells (Berchtold et al., 1999). However, a previous study in our
laboratory demonstrated that the P2X7 antagonists KN-62 and A43879 nearcompletely impaired ATP-induced YO-PRO-12+ uptake into canine monocytes
(Jalilian, 2011), suggesting that P2X7 is predominantly responsible for the dye
uptake into these cells.

104

As discussed above genomic DNA sequencing identified four non-synonymous
SNPs in the canine P2RX7 gene. Thus, compared to the human P2RX7 gene, in
which

over

100

non-synonymous

SNPs

have

been

identified

(http://www.ncbi.nlm.nih.gov/snp), the dog P2RX7 gene is remarkably nonpolymorphic. However this difference is most likely over represented at present,
as the P2RX7 gene has been sequenced and recorded for far more human than
canine subjects. The Arg270Cys SNP has not been previously reported,
although a similar SNP has been identified at the corresponding position in the
human P2RX7 gene, with a change in the amino acid residue from arginine to
histidine (Arg270His, rs7958311). Of note, this SNP results in partial loss of
human P2X7 function (Stokes et al., 2010). Thus, the Arg270Cys SNP, which
changes a positively charged arginine to the neutral cysteine in canine P2X7,
may also potentially reduce P2X7 function. In fact this SNP was found only in
one dog and in MDCK cells, both of which had low P2X7 function (Fig. 4.13A;
Table 4.3). The Arg365Gln SNP has also not been previously reported in dogs.
The Arg365Gln SNP, which changes a positively charged arginine to the neutral
glutamine, is located in the intracellular C-terminal domain. In humans, the
closest identified SNP to Arg365Gln is the partial loss-of-function SNP
Thr357Ser (rs2230911), which results in decreased ATP-induced inward
currents, dye uptake and intracellular mycobacteria killing (Shemon et al.,
2006). The Arg365Gln SNP was only found in heterozygous dosage and was
restricted to Labradors (pure or cross breed) with varying P2X7 function.
However, the Arg365Gln SNP did not correspond with altered P2X7 function in
canine monocytes (Fig. 4.13B). Of note, the three dogs containing the
Arg365Gln SNP with highest P2X7 function also contained the Pro452Ser SNP.
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Thus, it is possible that any potential loss-of-function of the Arg365Gln SNP
may have been neutralised by a potential gain-of-function of the Pro452Ser
SNP. However, the ability of Arg365Gln to alter P2X7 function remains
unknown. The Phe103Leu SNP is reported in the Ensembl database
(rs23314713), however no functional characterisation of this SNP has been
reported. The SNP is located in the extracellular loop of the P2X7 subunit, and
thus may have importance for agonist or antagonist binding. However, both
phenylalanine and leucine are non-polar amino acids, thus the substitution
may be of little biological significance and may explain why P2X7 function was
similar between wild-type dogs and dogs heterozygous or homozygous for this
SNP (Fig 4.13C). The Pro452Ser SNP is also reported in the Ensembl database
(rs22315462), however no functional characterisation has been done. The SNP
is located in the C-terminal domain of the P2X7 subunit, and thus may have
importance

for

pore

formation.

In

mouse

P2X7,

a

SNP

(Pro451Leu;

rs48804829) has been identified in position 451 (which corresponds to position
452 in dog P2X7). This SNP causes a decrease in ATP-sensitivity and impaired
P2X7 pore-formation compared to wild type P2X7 (Adriouch et al., 2002).
However, the Pro452Ser SNP did not correspond with altered P2X7 function in
canine monocytes (Fig 4.13D). This difference in effect between Pro452Ser in
the dog and Pro451Leu in the mouse may reflect differences in the side chains
of serine and leucine, which contain a hydroxyl (hydrophilic) group and
aliphatic (hydrophobic) side chain, respectively.
As noted above, the Arg270Cys and Pro452Ser SNPs were also identified in
MDCK cells (originally derived from a Cocker Spaniel) (Table 4.3). Both of these
were non-synonymous SNPs present in heterozygous dosage. Our group
106

previously found that MDCK cells expressed low amounts of functional P2X7
(Jalilian, 2011). Thus, this is consistent with the Arg270Cys SNP being
associated with a loss-of P2X7 function. In addition, a synonymous SNP (T→C)
was identified in position 131 (Asn131) in MDCK cells. This SNP was present in
heterozygous dosage in MDCK cells, as well as in heterozygous or homozygous
dosage in 13 of 19 dogs. The biological relevance of this SNP is unknown, but a
recent review highlights the potential importance of synonymous mutations to
human disease and in particular to translation of proteins (Sauna and KimchiSarfaty, 2011). However, given the presence of Asn131 in both dogs with high
and low P2X7 function, it appears unlikely this SNP is responsible for the
variation in P2X7 function between dogs.
Our group previously attempted to develop a protocol for amplification and
sequencing of exons 3 and 9 of the canine P2RX7 gene (Peranec, 2011, Bakhsh
and Sluyter, unpublished). However, only partial sequences (<15% of the total
exon) were obtained due to a low signal to background noise ratio. The current
study developed protocols for the amplification and sequencing of each of the
exons of the canine P2RX7 gene. In addition, a number of experiments were
conducted to optimise the sequencing conditions for each exon in order to get
high quality sequence data (results not shown). The developed protocols
allowed the sequencing of each exon of the P2RX7 gene, and will be of value
further sequencing of additional dogs.
In conclusion, this study confirmed that P2X7 function varies between dogs.
Moreover, four non-synonymous SNPs were identified in the canine P2RX7
gene, one of which may result in a loss-of P2X7 function. Future studies are
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planned using mutant canine P2X7 receptors to investigate if any of these
SNPs alter P2X7 function.
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Chapter 5: General Discussion
This thesis forms a part of an ongoing study aiming to investigate the role of
the canine P2X7 receptor in inflammation and immunity. First, the expression
of TLR4, P2X7, NALP3 and caspase-1 was confirmed in Madin-Darby canine
kidney (MDCK) cells (Chapter 2). Second, these cells were found to express IL1β and IL-18 (Chapter 2). Despite various attempts, however, IL-1β release
from MDCK cells could not be detected (Chapter 2). In contrast, LPS and ATP
but not LTA induced IL-1β release from canine whole blood, although a role for
P2X7 in this process could not be established (Chapter 2). Third, recombinant
P2X7

cloned

from

an

English

Springer

Spaniel

was

sequenced

and

characterised pharmacologically (Chapter 3). Two non-synonymous (missense)
SNPs were identified within this cloned receptor; Leu440Phe and Pro452Ser
(Chapter 3). Fourth, relative P2X7 function of monocytes was assessed in 22
dogs, and when combined with previous obtained data from another 43 dogs
(Jalilian, 2011, Peranec, 2011) showed that P2X7 function varied between and
within breeds. Fifth, sequencing of the canine P2RX7 gene identified four nonsynonymous

SNPs

(Phe103Leu,

Arg270Cys,

Arg365Gln

and

Pro452Ser)

(Chapter 4). Two of which were also found in MDCK cells: Arg270Cys and
Pro452Ser (Chapter 4). Neither the Phe103Leu, Arg365Gln or Pro452Ser SNPs
were associated with change of P2X7 function; in contrast, the Arg270Cys SNP
was associated with a loss of P2X7 function (Chapter 4).
The identification of TLR4, P2X7, NALP3, caspase-1, IL-1β and IL-18 mRNA in
MDCK cells suggests that MDCK cells may provide a useful model cell line to
study these molecules in canine epithelial cells. The presence of NALP3,
109

caspase-1, IL-1β and IL-18 in MDCK cells, however, needs to be confirmed at
the protein level. The current study attempted to detect IL-1β release from
MDCK cells unsuccessfully. The positive control nigericin, which is known to
induce IL-1β release independently of P2X7 activation (Sluyter et al., 2004b),
also failed to induce IL-1β release from MDCK cells, indicating that the
experimental conditions were insufficient to induce detectable IL-1β release
from MDCK cells. Further development of the procedure needs to be performed
in order to determine if MDCK cells can release IL-1β or IL-18.
The P2X7 function in MDCK cells has been shown to be relatively low (Jalilian,
2011). This was attributed to low expression of P2X7 protein; however, it is
possible that SNPs in the P2RX7 gene contributes to the low function. Two
non-synonymous SNPs were identified in MDCK cells: Arg270Cys and
Pro452Ser. These SNPs were also found in a King Charles Cavalier cross
Cocker Spaniel with low relative monocyte P2X7 function (Chapter 4). However
a comparison between relative P2X7 function of canine monocytes and
genotype showed that the Pro452Ser SNP did not correlate with a change in
P2X7 function. Moreover, this SNP was also present in the cloned canine P2X7
receptor which formed functional receptors in HEK 293 cells (Chapter 3), thus
it is unlikely this SNP codes for a loss of P2X7 function. In contrast, given that
the Arg270Cys SNP is associated with low P2X7 function in one dog and MDCK
cells, this SNP may result in a loss-of-function in P2X7. Furthermore, given
that this dog (a Cocker Spaniel cross) and MDCK cells (originally derived from a
Cocker Spaniel) both encode the Arg270Cys SNP it will be of future importance
to see if this SNP is confined to Cocker Spaniels and whether it is associated
with any specific disorders in this breed.
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The dog P2X7 receptor contains 86% sequence identity with the human P2X7
receptor,

making

the

dog

a

possible

future

model

for

studying

pharmacokinetics and side effects of P2X7 antagonists. The current study
pharmacologically characterised a recombinant P2X7 receptor cloned from an
English Springer Spaniel (Chapter 3). Generally, the recombinant P2X7
receptor exhibited a similar pharmacological profile to that of human P2X7
(Michel et al., 2009, Roman et al., 2009, Donnelly-Roberts et al., 2009), and
previously studied native and recombinant canine P2X7 (Roman et al., 2009,
Sluyter et al., 2007, Stevenson et al., 2009). Although differences between the
action of ATP and BzATP as full or partial agonists between the studies of our
group and that of Roman et al. (2009) remains to be resolved. P2X7 is an
important therapeutic target due to its role in inflammatory responses and
pain sensitivity, and its association with numerous diseases including
autoinflammatory, neurological, renal disorders and cancer (Jelassi et al.,
2011, Goncalves et al., 2006, Skaper et al., 2010, Parvathenani et al., 2003).
The current study will help contribute to broader understanding of drug
interactions with the canine P2X7 receptor.
The current study showed that relative P2X7 function of monocytes varied
between dogs (Chapter 4) consistent with prior data from our group with the
same assay (Peranec, 2011, Jalilian, 2011). Of note, the Leu440Phe SNP
present in the cloned canine P2X7 receptor was not seen in 62 dog samples.
Whether this SNP represents a rare mutation, perhaps confined to English
Springer Spaniels, or a mutation arising from the cloning process remains to
be determined. Four non-synonymous SNPs were identified in the P2RX7 gene
of dogs by sequencing of genomic DNA (Phe103Leu, Arg270Cys, Arg365Gln
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and Pro452Ser; Chapter 4). In addition, ATP-induced IL-1β release in whole
blood varied between dogs, although a role for P2X7 in this process remains to
be established. P2X7-mediated IL-1β release in humans varies due to SNPs in
the P2RX7 gene (Sluyter 2004b, Stokes, 2011). Thus, these differences in
canine P2X7 activity may also be due to SNPs in the P2RX7 gene of dogs. A
summary of the five identified SNPs in the canine P2X7 receptor is illustrated
in Figure 5.1.

Figure 5.1: Non-synonymous single nucleotide polymorphisms of the canine
P2RX7 gene. Five non-synonymous SNPs were identified in the canine P2RX7 gene
encoding the following changes: Phe103Leu (exon 3), Arg270Cys (exon 8), Arg365Gln
(exon 11), Leu440Phe (exon 13) and Pro452Ser (exon 13).
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Future studies should include the generation of mutant P2X7 receptors by sitedirected mutagenesis to explore if any of these SNPs alter P2X7 function.
Moreover, future studies of canine monocytes and other cell types investigating
the possible contribution of P2X2,4 or 5 to ATP-induced organic dye uptake
should also be conducted to determine if these receptors contribute to the
variation in ATP-induced YO-PRO-12+ uptake into canine monocytes. Finally,
given the emergence of P2X7 splice variants in humans (Feng et al., 2006,
Adinolfi et al., 2010, Cheewatrakoolpong et al., 2005) and rodents (Masin et al.,
2012, Nicke et al., 2009), the presence of potential P2X7 splice variants in dogs
and their potential influence on P2X7-indiced pore formation needs to be
examined.
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